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ABSTRACT
Objective To determine whether adding web- based 
support (e- coachER) to an exercise referral scheme (ERS) 
increases objectively assessed physical activity (PA).
Design Multicentre trial with participants randomised 
to usual ERS alone (control) or usual ERS plus e- coachER 
(intervention).
Setting Primary care and ERS in three UK sites from 
2015 to 2018.
Participants 450 inactive ERS referees with chronic 
health conditions.
Interventions Participants received a pedometer, PA 
recording sheets and a user guide for the web- based 
support. e- coachER interactively encouraged the use of 
the ERS and other PA options.
Main outcome measures Primary and key secondary 
outcomes were: objective moderate- to- vigorous PA 
(MVPA) minutes (in ≥10 min bouts and without bouts), 
respectively, after 12 months. Secondary outcomes 
were: other accelerometer- derived and self- reported PA 
measures, ERS attendance, EQ- 5D- 5L, Hospital Anxiety 
and Depression Scale and beliefs about PA. All outcomes 
were collected at baseline, 4 and 12 months. Primary 
analysis was an intention to treat comparison between 
intervention and control arms at 12- month follow- up.
Results There was no significant effect of the 
intervention on weekly MVPA at 12 months between 
the groups recorded in ≥10 min bouts (mean difference 
11.8 min of MVPA, 95% CI: −2.1 to 26.0; p=0.10) or 
without bouts (mean difference 13.7 min of MVPA, 
95% CI: −26.8 to 54.2; p=0.51) for 232 participants 
with usable data. There was no difference in the primary 
or secondary PA outcomes at 4 or 12 months.
Conclusion Augmenting ERS referrals with web- based 
behavioural support had only a weak, non- significant 
effect on MVPA.
Trial registration number ISRCTN15644451.
INTRODUCTION
Low levels of physical activity (PA) are a significant 
contributor to a wide range of chronic physical and 
mental health conditions such as obesity, type 2 
diabetes, hypertension, osteoarthritis and depres-
sion1–6 and associated healthcare cost.7 Primary 
care exercise referral schemes (ERSs) have small 
positive effects on self- reported PA, compared with 
usual care. However, most of these trials are under-
powered, and do not necessarily include physically 
inactive participants with chronic conditions.8 9 
The format of ERS range from considerable exer-
cise practitioner contact at an exercise facility to a 
signposting service to community PA options with 
minimal sustained contact.10 This variation in ERS 
makes a broader national approach to improving the 
quality of the patient experience and effectiveness 
challenging. Given that only 66%–81% ever attend 
the referral scheme, that only 43%–49% complete 
it11 and that the health benefits seem to be small,12 
new ways are needed to improve uptake and adher-
ence to ERS, and to foster sustainable PA from 
ERS.13
Web- based interventions have been shown to 
be effective in supporting short- term changes 
in (mostly self- reported) PA among the general 
population and those with clinical conditions.14–18 
However, no studies have explored their use along-
side ERS offering face- to- face support. Along with 
service users, we developed a bespoke support 
system called e- coachER, using the LifeGuide plat-
form (https://www. lifeguideonline. org/), seeking 
to empower ERS participants with physical and 
mental health conditions to become more physi-
cally active and to remain motivated to do so. If 
shown to be an effective adjunctive intervention, 
such a system could be scaled up relatively cheaply 
and routinely offered to thousands of patients per 
year in hundreds of schemes in the UK.10
We undertook a multicentre parallel two- group 
randomised controlled trial to determine the impact 
of the addition of web- based behavioural support 
for ERS referral on PA and health outcomes in inac-
tive people with chronic disease.
METHODS
The trial was conducted and reported in accordance 
with the Consolidated Standards of Reporting 
Trials guidelines.19 Our full trial protocol has been 
published elsewhere so we limit the details provided 
here.20
Study population
Between July 2015 to March 2017, we recruited 
low active adults with at least one chronic condition 
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(from obesity, hypertension, type 2 diabetes, lower limb osteo-
arthritis and depression) in Greater Glasgow, Birmingham or 
Plymouth and adjacent rural areas, who had been or were about 
to be referred by a primary care practitioner to a local ERS. For 
a full list of inclusion/exclusion criteria see online supplemental 
material (online supplemental appendix 1). For a full list of ways 
in which participants were recruited see online supplemental 
material (online supplemental appendix 2).
Study procedures
A summary of the recruitment procedures is shown in a flow 
chart in online supplemental material appendix 3, and full 
procedures were previously reported.20
Randomisation and blinding
Participants were randomly allocated 1:1 to either usual ERS 
alone (control arm) or usual ERS plus e- coachER (intervention 
arm). Randomisation was stratified by site with minimisation 
by the participant’s perceived main reason for their referral to 
the ERS (ie, chronic condition) and by self- reported IT literacy/
confidence using a 10- point scale.
Blinding to trial allocation among the trial statistician and 
most of the research team (excepting those involved in the qual-
itative process evaluation) was not broken until the primary and 
secondary analyses were reported to the Project Management 
Group.
Intervention
Participants allocated to the intervention group were mailed a 
small box containing a user guide for accessing the e- coachER 
web- based support system, a pedometer (step- counter) and a 
fridge magnet with tear- off sheets to record weekly step counts 
or minutes of moderate- to- vigorous PA (MVPA). The user guide 
provided a summary of the content on the website and guidance 
on how to register to access a range of interactive opportuni-
ties to enhance participants’ motivation to take up the ERS and 
to become more physically active, whether or not they engaged 
with their local ERS. A logic model for the intervention and a 
more detailed description of the content, in compliance with the 
TiDIER checklist and Behaviour Change Techniques mapping 
has been reported elsewhere.20
The interactive e- coachER support system adopted effective 
features from other interventions.21 It involved seven ‘Steps to 
Health’ designed to take about 5–10 min each to complete each 
week. We defined getting to step 5 (setting a goal and reviewing 
a goal online) as a sufficient ‘dose’ of the intervention to impact 
on minutes of MVPA, although we recognise that merely mailing 
a pedometer could, for some, be an effective intervention.22
Control
Participants in both arms of the trial were offered usual primary 
care ERS, across three different schemes, as described else-
where,20 to increase the generalisability of the trial.
Data collection
At 4 and 12 months post randomisation, participants were sent 
an accelerometer and questionnaire booklet by post, and prepaid 
envelope to return to Peninsula Clinical Trials Unit. Reminder 
letters and phone calls aimed to increase follow- up rates. Partic-
ipants returning the device received an online/high street store 
voucher for £20 on each occasion.
Outcomes measures
The primary outcome was the number of weekly minutes of 
MVPA, recorded in ≥10 min bouts, measured objectively by 
GENEActiv Original accelerometer (Activinsights; https://
www. geneactiv. org/), over a 1- week period at 12 months post 
randomisation. A description of our procedures for processing 
accelerometer data is provided in online supplementary material 
appendix 4. Briefly, GENEActiv PC software (V.3.0_09.02.2015) 
was used with software R using package GGIR V.1.2-8 (https:// 
cran. r- project. org/ web/ packages/ GGIR/ index. html)23 to identify 
data for the primary analysis if participants achieved a minimum 
of 16 hours of wear time for a minimum of 4 days (including at 
least 1 weekend day).
Other accelerometer recorded and self- reported secondary 
outcomes at 4 and 12 months are shown in online supplemental 
material appendix 5 and table 1. Initial attendance at the ERS 
was captured from ERS providers with imputed participant- 
reported attendance at 4 weeks and/or 4 months where the 
ERS service data were missing. Engagement with the e- coachER 
intervention was captured using the LifeGuide platform. Other 
methods and data used for our health economic evaluation and 
process evaluation are reported elsewhere.20
Statistical analysis
In the absence of a published minimally important difference 
for MVPA, we assumed a ‘small- to- moderate’ standardised effect 
size of 0.35, and estimated that 413 participants were required 
at 88% power and a two- sided alpha of 5% assuming for 20% 
attrition, or 90% power at a two- sided alpha of 5% allowing for 
16% attrition (using ‘sampsi’ in STATA V.14.2). Based on the 
baseline SD for MVPA total weekly minutes in ≥10 min bouts of 
104 to 113,24 an effect size of 0.35 would correspond to a mean 
between group differences of 36–39 min of MVPA per week at 
12- month follow- up.
All statistical analyses were conducted to a predefined anal-
ysis plan prior to end of data collection and any comparison 
of follow- up outcomes. The primary analysis compared primary 
and secondary outcomes between groups in accordance with 
the principle of intention to treat (ITT) (ie, based on original 
random allocation) in participants with complete outcomes at 
12 months, adjusting for baseline outcome values and stratifica-
tion and minimisation variables. Following assessment of base-
line demographics, mean age and gender were also added to the 
adjusted model.
Two secondary analyses were undertaken to compare groups 
across all follow- up points using a mixed model repeated 
measures approach and complier average causal effect (CACE) 
analyses undertaken to examine the impact of adherence to the 
intervention, (ie, (a) simply registering to access the website or 
not and (b) completing five or more ‘Steps to Health’ or not) on 
primary and secondary outcomes at 12 months.
The primary analysis model was extended to fit interac-
tion terms to explore possible subgroup differences in inter-
vention effect in stratification and minimisation variables for 
the primary outcome at 12 months. Given the low power for 
testing interactions, these results were treated only as explor-
atory. Sensitivity analyses were conducted for four additional 
wear time criteria (see online supplemental table appendix 6): 
Multiple imputation was used to replace missing outcome data 
using baseline outcomes and other explanatory covariates (eg, 
treatment group, age), assuming unobserved measurements were 
missing at random. Given that the proportion of patients with 
missing accelerometry data was <3% out of the total number 
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of participants who fulfilled the wear time criteria of includable 
PA data (n=243), no imputation was undertaken for the accel-
erometry related primary and secondary outcome. Using the 
same primary analysis model as described above, between- group 
outcomes were compared in ITT complete case and imputed 
data sets for non- accelerometry related secondary outcomes at 
12 months. All analyses were conducted by a blinded statistician 
using STATA V.14.2.
Patient and public involvement (PPI)
PPI representatives with diverse clinical conditions and experi-
ence of ERS provided critical feedback on the development and 
usability of the intervention, trial participant- facing documents, 
participant newsletter, on recruitment and trial retention issues, 
and interpretation of the findings and dissemination. Other 
stakeholders involved in the delivery of ERS such as managers 
and practitioners were also consulted in each site.
Process evaluation and economic evaluation
Findings from an embedded process evaluation and economic 
evaluation will be presented elsewhere.
RESULTS
Participant flow through the trial
Figure 1 shows the flow of participants through the trial. The 
reasons for ineligibility at each stage of recruitment are shown in 
online supplemental material appendix 7. Of the 450 participants 
randomised, 232 met our pre set, primary outcome wear time 
threshold (at baseline and 12 months). There was no evidence 
of differences in the demographic characteristics of those 
participants who provided primary outcome data at 12 months 
compared with those that did not provide this follow- up data.
Baseline participant characteristics
Table 2 shows the baseline characteristics of the 450 randomised 
participants as a whole and by trial arm. While in general the 
two arms were well balanced, we noted some small differences 
within categories in respect of education status though numbers 
in each category were small.
Approximately one- third of participants were recruited from 
each of the three sites. As an indication of the level of multi-
morbidity in the sample, 74.2% had two conditions, 30.7% had 
three conditions and 11.8% had four or more conditions.
There was a distinct difference at baseline, for the whole 
sample, between the mean (SD) weekly accelerometer MVPA 
minutes when recorded in ≥10 min bouts (31.0 (83.4)) and 
without bouts (346.0 (251.5)), and the proportion of the whole 
sample who achieved 150 min/week when recorded in ≥10 min 
bouts (4%) and without bouts (80%). These figures compared 
with self- reported data which showed a mean (SD) of 208.8 
(364.0) minutes and 36% achieving 150 min/week.
Intervention engagement
Among intervention participants, 36% did not register and 
log into the e- coachER website, and 36% progressed through 
to at least step 5. The proportion reaching each step is shown 
in online supplemental material appendix 8. The mean (SD) 
number of goal reviews was 2.5 (SD 4.5) with a range of 0–24. 
The 144 participants who registered, logged into e- coachER for 
a mean (SD) and median number of times of 14.1 (16.7) and 
6, respectively, with a range from 1 to 101. Those who regis-
tered spent an estimated mean (SD) and median time engaging 
with the e- coachER web- based support of 48.4 (41.9) min and 
36 min, respectively, with a range of 6–186 min.
Primary outcome
Table 3 shows the primary outcome summary scores at baseline, 
4 and 12 months follow- up. Primary analysis showed a (non- 
significant) weak indicative effect in favour of the intervention 
at 12 months (mean difference 11.8 weekly minutes of MVPA, 
95% CI: −2.1 to 26.0, p=0.10). Given the over dispersion and 
high frequency of zero values in the primary outcome, and the poor 
fit of the primary analysis model, alternative post- hoc regression 
models were explored. These included: log transformed mixed 
Table 1 Summary of secondary outcomes at baseline and 4 and 12 months follow- up and analysis of between group differences at 12 months
Baseline 4- month follow- up 12- month follow- up
Between group difference or 
OR at 12 months*
Mean (95% CI) P value
Control Mean (SD) 
Median (IQR) or 
n/N (%)
Intervention Mean 
(SD) Median (IQR) or 
n/N (%)
Control Mean (SD) 
Median (IQR) or 
n/N (%)
Intervention Mean 
(SD) Median (IQR) 
or n/N (%)
Control Mean (SD) 
Median (IQR) or 
n/N (%)
Intervention Mean 
(SD) n, Median 
(IQR) or n/N (%)
Achievement of at least 
150 min of weekly MVPA 
in ≥10 min bouts†
8/201 (4%) 9/207 (4%) 2/128 (2%) 7/109 (6%) 3/133 (2%) 6/110 (5%) OR: 3.80 (0.16 to 20.92), 0.12
Achievement of at least 
150 min of weekly MVPA†
149/201 (74%) 178/207 (86%) 98/128 (76%) 99/109 (91%) 99/133 (74%) 93/110 (85%) OR: 1.67 (0.82 to 3.42), 0.16
Self- reported MVPA 
weekly minutes
N=220, 213.5 (352.7)
65.0 (0–285.0)
N=220, 204.0 (375.6)
47.5 (0–247.5)
N=183, 318.0 (517.6)
95.7 (0–305.2)
N=166, 306.1 (430.5)
105.0 (0–314.1)
N=170, 228.3 (424.4)
85.0 (0–285.0)
N=154, 252.7 (426.2)
130.0 (0–320.2)
49.3 (−36.3 to 135.0) 0.26
Achievement of at least 
150 min of weekly MVPA 
self- reported
83/220 (37%) 77/220 (48%) 94/183 (51%) 88/166 (53%) 76/170 (45%) 76/154 (49%) OR: 1.23 (0.79 to 1.90), 0.36
Average daily diurnal 
inactivity (hours)†
N=199, 1.7 (1.1) N=205,
1.5 (1.1)
N=125, 1.4 (1.1) N=109,
1.4 (0.9)
N=99, 1.4 (1.0) N=78,
1.5 (1.0)
0.6 (0.5 to 0.7),<0.0001
Average daily sleep 
(hours)†
N=199, 6.8 (1.5) N=205,
6.9 (1.2)
N=125,
6.7 (1.3)
N=109,
6.7 (1.4)
N=128,
6.8 (1.5)
N=110,
7.0 (1.5)
0.3 (−0.1 to 0.6), 0.11
EQ- 5D- 5L (Devlin values) N=216, 0.74 (0.24) N=215,
0.76 (0.23)
N=162, 0.72 (0.26) N=148,
0.76 (0.25)
N=158, 0.72 (0.26) N=138,
0.73 (0.27)
0.00 (−0.4 to 0.05) 0.89
HADS- D N=217, 7.6 (4.5) N=214,
7.4 (4.7)
N=164,
7.4 (4.8)
N=147,
6.0 (4.7)
N=156, 7.1 (4.8) N=139,
6.3 (5.1)
−0.2 (−1.0 to 0.6), 0.44
HADS- A N=217, 8.7 (4.6) N=214,
8.6 (5.1)
N=164, 8.5 (4.8) N=146,
7.5 (5.0)
N=156,
8.4 (4.8)
N=139,
7.6 (5.2)
−0.5 (−1.2 to 0.2), 0.20
Median (IQR) reported for accelerometry and self- report continuous PA outcomes only.
*Adjusted for baseline MVPA, age, gender, site and minimisation variables.
†Non- bouted accelerometer recorded MVPA adjusted for baseline outcome value, age, gender, site and minimisation variables.
HADS- A, Hospital Anxiety & Depression Scale - Anxiety; HADS- D, Hospital Anxiety & Depression Scale - Depression; MVPA, moderate- to- vigorous physical activity.
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effects (with a constant added), mixed effect model with outliers 
removed, negative binomial and zero- inflated binomial models. 
These alternative models confirmed the interpretation of our 
primary analysis (see online supplemental material appendix 9 
that also includes model fit graphs). The non- significant between 
group difference in primary outcome was consistent across the 
primary and post- hoc models.
CACE analyses for the primary outcome showed a mean differ-
ence of 22.9 weekly minutes of MVPA (95% CI: −3.4 to 47.8, 
p=0.09) in favour of the ERS group. There was no evidence of 
any interactions between stratification variables (site and reason 
for ERS referral), age and gender with the intervention effect for 
the primary outcome at 12 months. Sensitivity analysis showed 
that wear time (ie, days per week, hours per day, etc) did not 
influence the findings.
Secondary outcome findings
Table 1 shows the summary descriptive secondary outcomes at 
baseline and 4 and 12 months follow- up. No significant differ-
ences in the primary analysis for any of the secondary outcomes 
at 12 months were seen except for intervention participants 
spending more time in daily diurnal inactivity (sedentary time) 
at 12 months. Secondary analysis models compared imputed 
secondary outcome data sets at 12 months and repeated 
measures analysis of primary and secondary outcomes at both 
4 and 12 months were broadly consistent with the primary anal-
yses results above.
There was no difference in ERS uptake, between the control 
group, 173/223 (78%) and intervention group, 167/223 (75%).
Serious adverse events (SAEs)
In total, 42 SAEs were reported in 35 participants and were all 
deemed to be either ‘not related’ or ‘unlikely to be related’ to the 
trial. In the control group, there were 26 SAEs among 21 partic-
ipants, and in the intervention group there were 16 SAEs among 
14 participants. One SAE was reported as a life- threatening 
event (asthma attack), all other SAEs were hospitalisations. See 
online supplemental material appendix 10.
DISCUSSION
Summary of findings
To our knowledge this is the first randomised study to assess the 
effects of adding web- based behavioural support to usual ERS 
support on objectively assessed long- term minutes of MVPA 
among participants with chronic physical and mental health 
conditions. Augmenting usual ERS using web- based behavioural 
support (e- coachER) provided a (none statistically significant) 
weak indicative effect on objectively assessed minutes of MVPA 
(when recorded in ≥10 min bouts or not) at 12 months among 
inactive or moderately inactive patients. Various sensitivity anal-
yses supported these findings. We also found no evidence of 
benefit in terms of ERS uptake and patient- reported outcomes. 
The extent of engagement with e- coachER was modest, but this 
factor did not influence the findings.
Figure 1 Participant flow chart. aReasons for ineligibility shown in online supplemental material appendix 7. ERS, exercise referral scheme.
 on N
ovem
ber 27, 2020 by guest. P
rotected by copyright.
http://bjsm
.bm
j.com
/
B
r J S
ports M
ed: first published as 10.1136/bjsports-2020-103121 on 27 N
ovem
ber 2020. D
ow
nloaded from
 
5Taylor A, et al. Br J Sports Med 2020;0:1–8. doi:10.1136/bjsports-2020-103121
Original research
Table 2 Baseline characteristics by study group and for the whole sample (N=450 unless stated)
Control group Intervention Both groups
N 226 224 450
Gender—n male (%) 84 (37) 76 (34) 160 (36)
  Age—mean (SD) (range) 51 (14)
(18–75)
50 (13)
(20–73)
50 (12)
(18–75)
BMI—mean (SD) (range) 32.5 (4.4)
(18.8–40.5)
32.7 (4.5)
(18.8–40.4)
32.6 (4.4)
(18.8–40.5)
GP PAQ Score—n (%)
  2 (inactive) 144 (63.7%) 149 (66.5%) 293 (65.1%)
  3 (moderately inactive) 82 (36.3%) 75 (33.5%) 157 (34.9%)
Ethnicity—n (%)
  White 195 (86.3%) 179 (79.9%) 374 (83.1%)
  South Asian 11 (4.9 %) 16 (7.2 %) 28 (6.2 %)
  Other 20 (8.8 %) 28 (12.6 %) 48 (10.7 %)
Relationship status—n (%)
  Single, widowed, divorced, or dissolved or surviving civil partnership 124 (54.9%) 112 (50%) 236 (52.4%)
  Married or civil partnership 102 (45.1%) 112 (50%) 214 (47.6%)
Domestic residence status (live with …)—n (%)
  Live alone 59 (26.1%) 48 (21.4%) 107 (23.8%)
  Live with others (eg, parent, child, other family or non- family member 
or partner)
167 (73.9%) 176 (78.6%) 343 (76.2%)
Education status—n (%)
  No qualifications 52 (23.0%) 29 (12.9%) 81 (18.0%)
  GCEs 146 (64.6%) 162 (72.3%) 308 (68.4%)
  A- level 71 (31.4%) 96 (42.9%) 167 (37.1%)
  First degree or above 58 (25.6%) 74 (33%) 132 (29.3%)
  Other 108 (47.8%) 104 (46.4%) 212 (47.1%)
Participant’s perceived possible reason versus main reason for GP referral—n (%)
Prediabetes or diabetes 55 (24.8) versus 24 (11) 57 (26.5) versus 25 (12) 112 (25.6) versus 49 (11)
  Lower limb osteoarthritis 64 (28.3%) versus 27 (12) 45 (20.1) versus 26 (12) 109 (24.2) versus 53 (12)
  Weight loss 182 (80.5) versus 114 (50) 182 (81.3) versus 113 (50) 364 (80.9) versus 227 
(50)
  Low mood 122 (54.0) versus 42 (18) 121 (54.0) versus 42 (19) 243 (54.0) versus 84 (19)
  High blood pressure 79 (35.0) versus 19 (8) 68 (30.4) versus 18 (8) 147 (32.7) versus 37 (8)
Smoking status—n (%)
  Smoker 34 (15.0%) 32 (14.3%) 66 (14.7%)
  Ex- smoker 90 (39.8%) 89 (39.7%) 179 (39.8%)
  Never smoked 102 (45.1%) 103 (46.0%) 205 (45.6%)
IT literacy/confidence level—n (%)1
  Low 36 (16%) 35 (16%) 72 (16%)
  High 190 (84%) 189 (84%) 379 (84%)
Site—n (%)
  Birmingham 78 (34%) 76 (34%) 154 (34%)
  Glasgow 69 (31%) 72 (32%) 141 (31%)
  Plymouth 79 (35%) 76 (34%) 155 (35%)
Weekly MVPA minutes (in ≥10 min bouts)—n, mean (SD)*Median (IQR) 201, 30.2 (105.8)
201, 0 (0, 23.3)
207, 31.8 (53.7)
207, 7.5 (0, 41.1)
408, 31.0 (83.4)
408, 0 (0–30.3)
Weekly MVPA minutes (no bouts)—n, mean (SD)* Median (IQR) 201, 319.5 (249.5)
264.6 (147.0–395.5)
207, 371.8 (251.3)
309.4 (196.7–490.7)
408, 346.0 (251.5)
288.4 (172.9–455.0)
n (%) achieving 150 min (in ≥10 min bouts)* 8/201 (4%) 9/207 (4%) 17/408 (4%)
n (%) achieving 150 min (no bouts)* 149/201 (74%) 178/207 (86%) 327/408 (80%)
Self- reported weekly MVPA minutes—n, mean (SD) Median (IQR) 220 213.5 (352.7)
65.0 (0–285.0)
220 204.0 (375.6)
47.5 (0–247.5)
440 208.8 (364.0)
40 (0–210)
N (%) achieving 150 weekly minutes of self- reported MVPA 83/220 (37%) 77/220 (35%) 160/440 (36%)
EQ- 5D- 5L (Devlin)—n, mean (SD) 216, 0.74 (0.24) 215 0.76 (0.23) 431, 0.75 (0.24)
HADS- D—n, mean (SD) 217, 7.6 (4.5) 214, 7.4 (4.7) 431, 7.5 (4.6)
HADS- A—n, mean (SD) 217, 8.7 (4.6) 214, 8.6 (5.1) 431, 8.6 (4.9)
On a 10 point Likert scale, scores of 1-5 indicated a low literacy level and scores of 6-10 a high literacy level.
*Accelerometer recorded.
BMI, body mass index; GCE, general certificate of education; GP PAQ, general practitioner physical activity questionnaire; MVPA, moderate- to- vigorous physical activity.
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Understanding the findings
Despite our best efforts, we were unable to get follow- up data 
from as many participants as we had planned and this may have 
reduced power to find a statistically significant effect. This has 
been a challenge for other ERS studies as well involving both 
device- based 25 and subjectively26 captured PA; for example, 
the latter study26 followed up only 55.6% of participants at 6 
months. The e- coachER study was initially powered to detect 
differences in numbers achieving 150 min of MVPA based on our 
systematic review.9 Due to early recruitment issues, the sample 
size was recalculated as reported, with the primary outcome 
based on ≥10 min bouts. The scant available data from device- 
based assessed PA in comparable trials made the power calcula-
tion somewhat uncertain, and we also need to know more about 
what is a clinically significant change in device- based assessed 
MVPA to justify sample sizes.
Our prespecified analysis plan, involving a measure of MVPA 
in bouts of ≥10 min, meant that a larger proportion of the 
sample than expected recorded zero minutes. This required us 
to explore a number of analysis models for the primary analysis, 
none of which were ideal but did provide a consistent conclu-
sion. Given that other studies have reported findings using 
a different accelerometer wear time (eg, Harris et al reported 
MVPA minutes from ‘at least 1 day’ to estimate weekly activity22 
we also considered our data with a range of wear time criteria, 
and again the findings were consistent.
The primary focus was on differences in MVPA minutes at 12 
months, but both groups showed an increase at 4 months. Our 
aim was to increase uptake and long- term change in MVPA, given 
concerns that ERS only foster short- term change,9 but providing 
the e- coachER intervention at the same time as what was some-
what effective ERS support may have limited the perceived need 
for e- coachER engagement. Also, digital support interventions 
are renowned for having relatively short- term engagement and 
effects, so it may be that greater digital support is needed after 4 
months (the typical duration of ERS).
In line with guidelines for ERS research,27 we tried to make 
the intervention as accessible as possible to participants from a 
wide range of socioeconomic backgrounds, which we achieved 
to some extent, but with an increasing array of devices for self- 
monitoring and setting goals for PA, and it may be that many 
participants in both arms of our sample were independently 
accessing these, which thereby negated any benefits from the 
e- coachER intervention.
Other considerations
We found a large discrepancy between the proportion of the 
sample who achieved 150 min of accelerometer recorded MVPA 
when assessed in ≥10 min bouts (4%) or not (80%), and by self- 
report (36%) at baseline, despite selecting sedentary or inactive 
participants for the trial. This finding also aligns with recently 
reported data from the USA, which identified a range of 3.4%–
95.6% of people achieving 150 min of MVPA depending on how 
the accelerometer data were processed.28 This is important given 
the recent removal of the ‘≥10 min bouts’ in UK and interna-
tional guidelines.29 30 It has been suggested that data collected 
using accelerometers is incompatible with guidelines of 150 min 
of MVPA per week and a value of about 1000 unbouted minutes 
of MVPA would need to be recommended for public health 
benefits.31 Our sample at baseline recorded only 346 min of 
unbouted weekly MVPA, which highlights the uniqueness of the 
study involving attempts to support change in such a low active 
sample, who potentially have the greatest to gain in terms of 
health from increases in MVPA.
A final consideration is that there was a small indication of 
imbalance in educational status between the groups at baseline, 
with a greater proportion of those with no qualification, and 
a slightly smaller proportion with higher qualifications, in the 
control group. However, given the relative small numbers of 
those in the respective categories for educational status, the fact 
that we had not specified inclusion of this variable in our statis-
tical analysis plan for the primary analysis, and the absence of 
between group differences in IT confidence, we chose not to 
further explore any confounding effects of educational status.
Further research
The focus on accumulating ≥10 min bouts for health benefit has 
now been dropped in global guidelines but in presenting both 
bouted and unbouted total MVPA the present study will provide 
valuable device- based information to inform future related 
research. Changes in international guidelines have removed 
the importance of completing PA in ≥10 min bouts, which in 
turn changes the basis for powering studies since a much greater 
proportion of the population are likely to meet the new unbouted 
target of 150 min of MVPA per week.
Practical implications
There remain digital opportunities to provide support for 
patients to facilitate greater uptake of ERS and sustained change 
in PA for the management of chronic conditions. Bespoke soft-
ware, drawing on some of the concepts and content in e- coachER 
could be used to ensure better links between the referee in 
primary care and patient. There can be confusion about what 
the ERS involves, compounded sometimes by delayed starting. 
Table 3 Summary of primary outcome data at baseline and 4 and 12 months follow- up and analysis of between group differences in total weekly 
minutes (recorded in bouts and no bouts) at 12 months
Baseline 4- month follow- up 12- month follow- up
Between group 
difference at 12 months*
Mean (95% CI) P value
Control (n=201) 
Mean (SD) 
Median (IQR)
Intervention 
(n=207) Mean (SD) 
Median (IQR)
Control
(n=128) Mean (SD) 
Median (IQR)
Intervention
(n=109) Mean (SD) 
Median (IQR)
Control
(n=133) Mean (SD) 
Median (IQR)
Intervention
(n=110) Mean (SD), 
Median (IQR)
Total weekly minutes of 
MVPA in ≥10 min bouts
30.2 (105.8)
0 (0–23.3)
31.8 (53.7)
7.5 (0–41.1)
30.9 (64.5)
0 (0–45.9)
38.4 (74.5)
0 (0–49.4)
18.7 (37.4)
0 (0–19.8)
35.4 (78.3)
0 (0–40.4)
11.8 (−2.1 to 26.0), 0.10
Total weekly minutes of 
MVPA†
319.2 (249.2)
264.6 (147.0–
395.5)
371.7 (251.3)
309.4 (196.7–490.7)
324.1 (264.6)
257.6 (151.2–375.2)
408.1 (251.3)
340.2 (231.7–521.5)
298.2 (210.7)
252.0 (144.2–420.0)
363.3 (256.2)
303.8 (186.9–469.0)
13.7 (−26.8 to 54.2), 0.51
Data from participants included as per primary analysis with 232 participants providing data at baseline and 12 months, and of these, from the 172 who provided data at 4 months.
*Adjusted for baseline MVPA, age, gender, site and minimisation variables.
†Unbouted minutes.
MVPA, moderate- to- vigorous physical activity.
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Beyond the formal ERS, digital systems could be implemented to 
maintain long- term MVPA.
CONCLUSION
Augmenting ERS referrals with web- based behavioural support 
had only a weak, non- significant indicative effect on acceler-
ometer recorded MVPA at 12 months, and no effect on ERS 
engagement. Overall, there was only modest engagement in the 
e- coachER web- based support, but degree of engagement did 
not influence the overall findings.
What are the key findings?
 ► With lower than desired follow- up rates, we found no 
significant effect of augmenting usual primary care exercise 
referral schemes with the e- coachER intervention on 
12 month objectively assessed physical activity (PA), among 
low active participants with chronic conditions.
 ► Engagement in the web- based support was modest despite 
being based on contemporary behaviour change theories, 
other effective interventions and good public and patient and 
stakeholder involvement in the development.
How might it impact on clinical practice in the future?
 ► The study was conducted pre COVID 19 and the need to 
find effective digital support for patients to facilitate greater 
uptake of exercise referral scheme (ERS) and sustained 
change in PA for the management of chronic conditions has 
only increased.
 ► Local digital solutions could be developed in primary care to 
better manage and monitor the progress of patients in an 
ERS to inform further conversations about self- management 
of chronic conditions.
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Supplementary material - Appendix 1: Full list of inclusion/exclusion criteria 
 
Inclusion criteria: 
 Aged between 16 and 74 years inclusive 
 Had one of more of the following conditions: 
o obesity i.e. a body mass index of 30–40 kg/m2 
o hypertension 
o pre-diabetes 
o type 2 diabetes 
o lower limb osteoarthritis 
o current or recent history of treatment for depression 
 Categorised as ‘inactive’ (i.e. 0 hours per week of physical exercise and in a sedentary 
occupation) or ‘moderately inactive’ (i.e. some activity but < 1 hour per week and in a 
sedentary occupation or 0 hours per week of physical exercise and in a standing occupation) 
according to the General Practice Physical Activity Questionnaire (GPPAQ).1 
 
Patients were excluded for the following reasons: 
 Did not meet the eligibility criteria for their local ERS 
 Had an unstable, severe and enduring mental health problem 
 Were being treated for an alcohol or drug addiction that may have limited their involvement 
with the study 
 Were unable to use written materials in English, unless there was a designated family 
member or friend to act as translator. 
 
 
1. Ahmad S, Harris T, Limb E, et al. Evaluation of reliability and validity of the General Practice 
Physical Activity Questionnaire (GPPAQ) in 60-74 year old primary care patients. BMC Fam 
Pract 2015;16:113. doi: 10.1186/s12875-015-0324-8 [published Online First: 2015/09/04] 
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Supplementary material - Appendix 2: Routes of approaching potential participants  
 
Patients were identified as potentially eligible for the trial in a number of different ways: 
 
 By health-care professionals in primary care at the point of being actively referred to an ERS 
or having been opportunistically found to be eligible for an ERS at a consultation with the 
primary care practitioner. 
 Via a search of patient databases at the participating GP practices (conducted by the local 
NIHR Primary Care Research Network team). 
 Via patient self-referral to the GP arising from community-based publicity for the trial. 
 By the ERS programme administrator on receipt of an ERS referral form from a GP practice. 
 By exercise advisors at the ERS service at enrolment on the ERS. With the patient’s consent, 
the exercise advisor provided the local researcher with the patient’s contact details for the 
purposes of the trial. 
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Supplementary material - Appendix 4: Data reduction decisions for processing accelerometers for the e-
coachER study 
   
Epochs: 5 
Valid day criteria:  16 hours  
Number of valid days: 4 including 1 weekend day 
Cut points  Converted from SVMgs to Milli-g values1 
Daily Analysis period  Midnight to Midnight  
 
 
1. Esliger DW, Rowlands AV, Hurst TL, et al. Validation of the GENEA Accelerometer. Medicine and science in 
sports and exercise 2011;43(6):1085-93. doi: 10.1249/MSS.0b013e31820513be [published Online 
First: 2010/11/23] 
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Supplementary material – Appendix 5: Accelerometer recorded and self-reported secondary outcome 
measures at 4 and 12 months 
 Total weekly minutes of MVPA in ≥10 minute bouts, measured objectively by accelerometer, over 
one week at four months. 
 Achievement of at least 150 minutes of MVPA, measured objectively by accelerometer, over one 
week at four and twelve months. 
 Self-reported achievement of at least 150 minutes of MVPA over one week using the 7 day recall of 
PA1 (7-day PAR) at four and twelve months.  
 Self-reported weekly minutes of MVPA at four and twelve months.  
 Average daily hours of sedentary behaviour measured objectively by accelerometer over one week 
at four and twelve months. 
 Self-reported average daily hours of sleep over one week at four and twelve months. 
 Self-reported health-related quality of life, assessed by the EQ-5D-5L2 at four and twelve months. 
 Self-reported symptoms of anxiety and depression, assessed by the Hospital Anxiety and Depression 
Scale3 at four and twelve months. 
 
1. Blair SN, Haskell WL, Ho P, et al. Assessment of habitual physical activity by a seven-day recall in a 
community survey and controlled experiments. Am J Epidemiol 1985;122(5):794-804. [published 
Online First: 1985/11/01] 
2. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of 
EQ-5D (EQ-5D-5L). Qual Life Res 2011;20(10):1727-36. doi: 10.1007/s11136-011-9903-x [published 
Online First: 2011/04/12] 
3. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67(6):361-70. 
[published Online First: 1983/06/01] 
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Supplementary material - Appendix 6: Additional wear time criteria used in the sensitivity analysis 
Sensitivity analysis were conducted for the following four additional wear time criteria:  
1) ≥16 hours over any four days (irrespective of week/weekend);  
2) ≥10 hours for 4 days (including at least one weekend day);  
3) ≥10 hours over any four days (irrespective of week/weekend);  
4) A minimum wear criteria of 1 day for 10 hours but with individuals weighted by the number of valid days 
with a minimum of 10 hours wear. 
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Supplementary material - Appendix 7: Table showing reasons for ineligibility at each stage of recruitment  
After expression of interest received (n=831) Ineligible (n=11) 
No email/internet n=4 
Other reasons n=3 
Age outside range n=1 
Doesn’t meet ERS criteria n=1 
No clinical condition of interest n=1 
Too active (physically active occupation) n=1 
After person contacted (n = 755) Ineligible (n=23) 
No email/internet n=9 
Other/combined reasons n=6 
Doesn’t meet ERS criteria n=4 
No translator n=2 
Age outside range n=1 
Too active (physically active occupation) n=1 
After assessing for eligibility (n = 691) Ineligible at screening (n=201) 
BMI outside range n=104 
Too active on GPPAQ n=46 
No clinical condition of interest n=26 
Age outside range n=10 
No email/internet n=6 
Substance abuse problem n=3 
Other reasons n=3 
Doesn’t meet ERS criteria n=2 
BP outside range n=1 
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Supplementary material – Appendix 8: Table showing level of engagement at each intervention step  
 
Stage started Summary of content Number (% of 224 in intervention arm) 
Did NOT register  81 (36%) 
Step 1  Quiz on benefits of PA 144 (64%) 
Step 2  Support to get active 133 (59%) 
Step 3 Encourage self-monitoring of steps 107 (48%) 
Step 4 Setting SMART step-count goals for next week 99 (44%) 
Step 5 Setting SMART goals for any PA for next week 96 (43%) 
Goal review Review goal and personalised feedback 81 (36%) 
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Appendix 9 – Model fit graphs and statistics for primary analysis and post-hoc regression for the 
primary outcome 
 
 Between group difference  
Mean (95% CI) P-value 
Primary analysis model 
Post-hoc model 1:  outliers [MVPA > 200] dropped  
Post-hoc model 2: log outcome + constant of 5 
Post hoc model 3: negative binomial model   
Post-hoc model 4: zero-inflated negative binomial model 
Mean difference: 11.8 (-2.1 to 26.0), 0.10 
Mean difference: 2.5 (-5.8 to 10.7), 0.55 
Mean difference: 1.2 (0.8 to 1.5), 0.27 
Rate ratio: 1.90 (0.90 to 4.00), 0.09 
Rate ratio: 1.59 (1.13 to 2.25), 0.01 
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Outliers [>200] dropped model 
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Log model with constant of 5 added 
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Supplementary material – Appendix 10: Tables showing Serious Adverse Events  
Serious Adverse Events (SAE) reported in the control group 
Participant ID 
(not study 
number)  
MedDRA organ 
system  
Summary description of event 
1 Neoplasms (2) Diagnosed with chronic myeloid leukaemia. 
2 Neoplasms (2) Prolonged hospitalisation due to recurrence of breast cancer. 
3 Psychiatric (7) Inpatient stay on mental health ward.  
2 Psychiatric (7) Hospitalised for depression. 
4 Nervous system (8) Morton's Neuroma. 
5 Respiratory (13) Treated in hospital for fluid on the lungs.  
6 Gastrointestinal (14) 
Varices of gastrointestinal tract. Prolonged inpatient stay due to 
major organ system involvement. 
7 Musculoskeletal (17) Admitted to hospital because unable to walk 
8 Pregnancy (19) Childbirth and post-natal inpatient stay. 
6 Investigations (23) Admitted to hospital with symptoms of meningitis. 
9 Investigations (23) Collapse. No diagnosis made.  
10 Surgical/medical (25) 
Planned admission for femorodistal bypass (peripheral vascular 
disease), subsequent infection/abscess behind knee. 
1 Surgical/medical (25) Hospitalised for treatment of boils in groin. 
11 Surgical/medical (25) Planned hospital admission for bunion removal. 
9 Surgical/medical (25) Planned hospital admission for bunion removal 
12 Surgical/medical (25) Hospital admission for treatment for diverticular bleeding. 
13 Surgical/medical (25) 
Injury to foot led to planned admission for partial amputation of 
left great toe. 
14 Surgical/medical (25) Planned hospital admission for right hip replacement. 
15 Surgical/medical (25) Planned hospitalisation for total hip replacement. 
16 Surgical/medical (25) Planned hospital admission for total knee replacement. 
17 Surgical/medical (25) Pre-planned hospitalisation for knee surgery due to osteoarthritis. 
18 Surgical/medical (25) Planned admission for total right knee replacement. 
18 Surgical/medical (25) 
Planned admission following infected right knee joint - continuing 
physio and using crutches. 
19 Surgical/medical (25) 
Hospitalisation for emergency operation on knee following a 
number of falls and pre-existing weakness in knee. 
20 Surgical/medical (25) Hospital admission for surgical repair of bulging disc in lower back. 
21 Surgical/medical (25) 
Hospitalised due to complications from type-2 diabetes and heart 
failure. 
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Serious Adverse Events (SAE) reported in the intervention group 
Participant ID 
(not study 
number) 
MedDRA organ 
system  
Summary Description of Event 
22 Cardiac (11) 
Admitted to hospital with abnormal ECG. Diagnosis: Paroxysmal 
Atrial Fibrillation 
23 Cardiac (11) Hospitalised due to heart attack 
24 Vascular (12) Hospitalised due to minor stroke. 
25 Respiratory (13) Asthma attack. 
26 Investigations (23) 
Hospital admission ?meningitis. No formal diagnosis made. 
Symptoms attributed to adverse effects of prescription medication. 
27 Investigations (23) 
Fall resulting in fracture of left radius. Admitted for investigations 
of reasons for the fall.  
28 Surgical/medical (25) 
Admitted to hospital following fall with fracture to right ankle and 
trauma to right knee 
29 Surgical/medical (25) Preplanned hospital admission for abdominal surgery 
30 Surgical/medical (25) Planned hospitalisation for operation on right ankle 
31 Surgical/medical (25) Admitted to hospital for 1 day (day case) due to osteoarthritis 
32 Surgical/medical (25) 
Planned hospital admission for tendon surgery on hand related to 
rheumatoid arthritis 
33 Surgical/medical (25) Hospital admission for treatment of rheumatoid arthritis flare-up. 
34 Surgical/medical (25) Inpatient stay for removal of Bartholin's cyst 
29 Surgical/medical (25) Planned hospital admission for knee replacement. 
28 Surgical/medical (25) Planned admission for partial right knee replacement 
35 Surgical/medical (25) 
Hospitalised for surgery on both knees, as treatment for long-
standing osteoarthritis. 
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AbstrACt
Introduction Physical activity is recommended for 
improving health among people with common chronic 
conditions such as obesity, diabetes, hypertension, 
osteoarthritis and low mood. One approach to promote 
physical activity is via primary care exercise referral 
schemes (ERS). However, there is limited support for 
the effectiveness of ERS for increasing long-term 
physical activity and additional interventions are needed 
to help patients overcome barriers to ERS uptake and 
adherence. This study aims to determine whether 
augmenting usual ERS with web-based behavioural 
support, based on the LifeGuide platform, will increase 
long-term physical activity for patients with chronic 
physical and mental health conditions, and is cost-
effective.
Methods and analysis A multicentre parallel two-group 
randomised controlled trial with 1:1 individual allocation 
to usual ERS alone (control) or usual ERS plus web-
based behavioural support (intervention) with parallel 
economic and mixed methods process evaluations. 
Participants are low active adults with obesity, diabetes, 
hypertension, osteoarthritis or a history of depression, 
referred to an ERS from primary care in the UK. The 
primary outcome measure is the number of minutes of 
moderate-to-vigorous physical activity (MVPA) in ≥10 
min bouts measured by accelerometer over 1 week at 12 
months. We plan to recruit 413 participants, with 88% 
power at a two-sided alpha of 5%, assuming 20% attrition, 
to demonstrate a between-group difference of 36–39 min 
of MVPA per week at 12 months. An improvement of this 
magnitude represents an important change in physical 
activity, particularly for inactive participants with chronic 
conditions.
Ethics and dissemination Approved by North West 
Preston NHS Research Ethics Committee (15/NW/0347). 
Dissemination will include publication of findings for 
the stated outcomes, parallel process evaluation and 
economic evaluation in peer-reviewed journals. Results 
will be disseminated to ERS services, primary healthcare 
providers and trial participants.
trial registration number ISRCTN15644451; Pre-results.
IntroduCtIon   
Physical inactivity was found to cost the 
National Health Service (NHS) £455 million 
in 2013–2014 according to data collected by 
Clinical Commissioning Groups in the UK.1 
strengths and limitations of this study
 ► This is the first study to determine whether adding 
web-based interventions to primary care exercise 
referral schemes increases objectively assessed 
physical activity more than usual exercise referral 
schemes, after 1 year.
 ► The study includes inactive adults with one or more 
common chronic conditions.
 ► No physical health measures (except self-reported 
weight) were assessed in the study.
 ► It is expected that participants will have multiple 
chronic conditions, meaning the study may not be 
able to determine intervention effects on physical 
activity for each condition.
 ► Participants in the intervention arm will be invited 
to take part in in-depth qualitative interviews which 
may act as a cointervention.
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Evidence-based guidelines recommend both aerobic 
and strength training for improving health markers and 
quality of life among those with common chronic meta-
bolic conditions2–5 and musculoskeletal conditions,6 and 
mostly aerobic exercise for preventing and reducing 
depression.7 Public health guidelines of 150 min of 
moderate-to-vigorous physical activity (MVPA) per week 
are widely accepted but even small increases in physical 
activity and reduced sedentary time among the least 
active are likely to accrue health benefits.8 9 
Patients with obesity, hypertension, type 2 diabetes, 
osteoarthritis and depression are less physically active 
than the general population,2 and need greater support 
to overcome real and perceived barriers to increase phys-
ical activity. Increases in physical activity among the least 
active have the potential to provide the largest impact on 
health but any benefits dissipate without maintained levels 
of activity.10 A variety of initiatives have been explored to 
promote physical activity within primary care, including 
referring patients to ‘exercise on prescription’, that is, 
an exercise referral scheme (ERS). In the UK, ERS have 
been common for promoting physical activity, with an 
estimated 600 schemes involving up to 100 000 patients 
per year.11
Evidence from a meta-analysis of eight randomised 
trials involving 5190 participants eligible for ERS12 
indicated a small increase in the proportion of partic-
ipants who achieved 90–150 min of physical activity of 
at least moderate intensity per week, compared with 
no exercise control at 6–12 months follow-up among 
at-risk individuals. But uncertainty remains regarding 
the effects for patients with specific medical conditions 
since no study assessed long-term physical activity objec-
tively, and many of the eight studies reviewed had rela-
tively small sample sizes.
A systematic review13 reported an average ERS uptake 
(attendance at the first ERS session) that ranged from 
66% in observational studies to 81% in randomised 
controlled trials, and average levels of adherence from 
49% in observational studies to 43% in randomised 
controlled trials. Predictors of uptake and adherence 
have rarely been explored but it has been reported that 
while women were more likely to begin an ERS, they were 
less likely to adhere to it than men; also, older people 
were more likely to begin and adhere to an ERS.13 ERS 
may help patients become familiar with concepts such as 
exercise type, intensity, frequency and duration of exer-
cise, matched to their medical condition, and target key 
processes of behaviour change. However, the following 
features of an ERS may reduce uptake and adherence: 
inconvenience, cost, limited sustainable physical activity 
support (eg, for 10 weeks) and low appeal for structured 
exercise and/or the medical model, that is, ‘exercise on 
prescription’, which may do little to provide autonomous 
support nor empower patients to develop self-deter-
mined behaviour to manage chronic medical condi-
tions.11 14 It therefore appears that additional support 
may be needed which is accessible, low cost, can be 
tailored to support a wide range of individual needs and 
empowers patients to develop and use self-regulatory 
skills (eg, self-monitoring, goal setting) to self-manage 
their chronic conditions. A wide variety of online and 
mobile technologies have been developed and used to 
support changes in and maintenance of physical activity.
There is considerable evidence on the effects of tech-
nology-based interventions for promotion of physical 
activity.15 16 These include studies with a wide range 
of interventions (from quite simple self-monitoring to 
interventions with complex multiple behaviour change 
components), targeted at different clinical groups 
with different baseline levels of physical activity, with 
various physical activity outcomes reported (very few 
using objective measures), and with mostly short-term 
follow-ups. Also, some comparisons are between inter-
vention versus no intervention and others versus human 
contact, although none reports on the effects of adding 
web-based support to ERS. The impact for web-based 
and technology interventions on increasing phys-
ical activity is small to moderate (an effect size ≤0.4). 
However, there is evidence that more rigorous studies, 
interventions with more behaviour change components 
and ones targeted at less active populations are more 
effective.15 16 A systematic review17 has highlighted 
the importance of maximising sustained engagement 
in web-based interventions for enhancing change in 
the target behaviour. A recent study18 confirmed that 
self-monitoring of physical activity and tailored feed-
back were important to increase engagement, and peri-
odic communications helped to maintain participant 
engagement.
The LifeGuide platform (www. LifeGuideonline. org/) 
has been extensively used to develop and evaluate 
acceptability and impact of online behaviour change 
and self-management interventions with a variety of 
clinical groups, including in primary care.19–21 For 
example, adding online LifeGuide support to face-
to-face support showed a greater lasting reduction in 
obesity than face-to-face dietetic advice alone.22 The 
LifeGuide platform provides a researcher-led tool to 
develop interventions drawn from theory and evidence 
of effective techniques23 24 and provides the opportu-
nity to understand engagement and utility of different 
behaviour change components.
Following iterative development work and user group 
testing and involvement, drawing on some online modules 
used in other LifeGuide interventions,19 we developed 
a bespoke intervention, called ‘e-coachER’ to support 
patients with chronic physical and mental health condi-
tions who have been referred from primary care to an 
ERS to receive face-to-face support. Should the approach 
prove to be effective, there is considerable potential for 
the intervention to be scaled up for patients with obesity, 
hypertension, type 2 diabetes, osteoarthritis and risk of 
depression at probable low cost25 26 and also extend it for 
patients with other chronic medical conditions (eg, low 
back pain, heart disease, cancer).
H
e
n
d
e
rs
o
n
-L
ib
 &
 M
e
d
ia
 S
e
r. P
ro
te
c
te
d
 b
y
 c
o
p
y
rig
h
t.
 o
n
 D
e
c
e
m
b
e
r 2
3
, 2
0
1
9
 a
t U
n
iv
e
rs
ity
 o
f P
ly
m
o
u
th
 - L
ib
ra
ry
 A
.
h
ttp
://b
m
jo
p
e
n
.b
m
j.c
o
m
/
B
M
J
 O
p
e
n
: firs
t p
u
b
lis
h
e
d
 a
s
 1
0
.1
1
3
6
/b
m
jo
p
e
n
-2
0
1
8
-0
2
2
3
8
2
 o
n
 2
1
 S
e
p
te
m
b
e
r 2
0
1
8
. D
o
w
n
lo
a
d
e
d
 fro
m
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Br J Sports Med
 doi: 10.1136/bjsports-2020-103121–8.:10 2020;Br J Sports Med, et al. Taylor A
3Ingram W, et al. BMJ Open 2018;8:e022382. doi:10.1136/bmjopen-2018-022382
Open access
AIM And objECtIvEs
The overarching aim is to determine if e-coachER online 
support combined with usual ERS provides an effective 
and cost-effective approach to supporting increases in 
physical activity in people referred to ERS with a range of 
chronic conditions.
The specific objectives are as follows:
 ► To determine whether in the intervention arm 
compared with the control arm, there is an increase 
in the total weekly minutes of MVPA at 12 months 
postrandomisation.
 ► To determine whether in the intervention arm 
compared with the control arm there is an increase in 
the proportion of participants who:
 – take up the opportunity to attend an initial consul-
tation with an exercise practitioner;
 – maintain objectively assessed physical activity from 
4 to 12 months postrandomisation;
 – maintain self-reported physical activity from 4 to 12 
months postrandomisation;
 – have improved health-related quality of life at 4 
and 12 months postrandomisation.
 ► To quantify the additional costs of delivering the inter-
vention and determine the differences in health utili-
sation and costs between the intervention and control 
arms at 12 months postrandomisation.
 ► To assess the cost-effectiveness of the intervention 
compared with control at 12 months postrandomisa-
tion (incremental cost per quality-adjusted life-year 
(QALY)) and over the lifetime perspective (incre-
mental cost per QALY).
 ► To quantitatively and qualitatively explore whether the 
impact of the intervention is moderated by medical 
condition, age, gender and socioeconomic status, IT 
literacy or ERS characteristics.
 ► To quantitatively and qualitatively explore the mech-
anisms through which the intervention may impact 
on the outcomes, through rigorous mixed methods 
process evaluation and mediation analyses (if 
appropriate).
MEthods And AnAlysIs
This protocol is reported in accordance with the Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials guidance27 (http://www. spirit- statement. 
org/ spirit- statement/) for protocols of clinical trials 
and TIDieR guidelines28 (http://www. equator- network. 
org/ reporting- guidelines/ tidier/) for intervention 
description.
study design and setting
This is a multicentre parallel two-group randomised 
controlled trial with participant allocation to usual ERS 
alone (control) or usual ERS plus web-based behavioural 
support (intervention) with parallel economic and 
mixed methods process evaluations. The trial design is 
summarised in figure 1.
Recruitment to the trial will take place over a 21-month 
period (July 2015 to March 2017) in three areas in the 
UK, that is, Greater Glasgow, West Midlands and South 
West England (including Plymouth, Cornwall and Mid 
Devon). Only the latter includes some participants in 
more rural locations.
study population
The study population will include patients registered with 
a general practitioner (GP) surgery and who have been or 
are about to be referred to a local ERS for a programme 
of support to increase physical activity. Participants will be 
aged 16–74 years and have one of more of the following: 
obesity (body mass index (BMI), 30–40), a diagnosis of 
hypertension, prediabetes, type 2 diabetes, lower limb 
osteoarthritis or having a history of treatment for depres-
sion. Participants must also be categorised as ‘inactive’ or 
‘moderately inactive’ based on the GP Physical Activity 
Questionnaire,29 be contactable via email, and have some 
experience of using the internet. Patients are excluded if 
they meet any of the following criteria: have an unstable, 
severe and enduring mental health problem or are being 
treated for an alcohol or drug addiction that may limit 
their involvement with the study, do not meet the eligi-
bility criteria for their local ERS or are unable to use 
written materials in English unless a designated family 
member or friend can act as translator.
study procedures
Patient identification, approach and consent
Patients will be identified as potentially eligible for the 
trial (i) by healthcare professionals in primary care at 
the point of being actively referred to an ERS or having 
been opportunistically found to be eligible for an ERS 
at a consultation with the primary care practitioner, (ii) 
via a search of patient databases at the participating GP 
practices (conducted by the local Primary Care Research 
Network team), (iii) via patient self-referral to the GP 
arising from community-based publicity for the trial, (iv) 
by the ERS programme administrator on receipt of an 
ERS referral form from a GP practice or (v) by exercise 
advisors at the ERS service at enrolment on the ERS (with 
the patient’s consent, the exercise advisor will provide the 
local researcher with the patient’s contact details for the 
purposes of the trial).
Potentially eligible patients will be approached by 
the primary care practitioner or the local researcher, 
depending on how the patient was identified, or patients 
may self-refer to the local researcher in response to 
publicity campaigns. These various means of identifica-
tion and approach are designed to accommodate the vari-
ation in usual care referral pathways to ERS across the 
participating sites and individual GP practices.
Amenable patients will be offered a study-specific 
Participant Information Sheet, either by post, via 
email or by hand (the route used will largely depend 
on the preference of the participating GP practice 
or ERS service). Interested patients will be asked to 
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communicate their expression of interest to the local 
researcher via a prepaid reply slip, by telephone or by 
email. On receipt of an expression of interest, the local 
researcher will contact the potential participant by tele-
phone to discuss the trial, confirm eligibility and take 
informed consent.
Figure 1 Trial design/participant pathway.
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baseline assessment
Consented participants will attend a baseline assess-
ment with the local researcher. This assessment will be 
conducted over the telephone, or in person at the GP 
practice or at the centre delivering the ERS or another 
convenient community location. Demographic data 
will be collected. The participant will be issued with a 
wrist-worn waterproof accelerometer (GENEActiv Orig-
inal accelerometer http://www. geneactiv. org/) to wear 
constantly for one whole week (day and night), and a 
self-report questionnaire booklet to complete at the 
beginning of the week-long period. The accelerometer 
will be worn on the wrist of the non-dominant hand (ie, 
the hand not favoured for writing). After 1 week’s wear, 
participants will post the accelerometer and completed 
questionnaire to the Peninsula Clinical Trials Unit (CTU) 
in pre-addressed envelopes provided using a prepaid 
postal service. The measures collected at baseline and 
follow-up are shown in table 1.
randomisation
On receipt of the baseline accelerometer at the CTU after 
1 week’s wear, participants will be randomised. Randomi-
sation will be stratified by site with minimisation by the 
participant’s perceived reason for their referral to the ERS 
(ie, weight loss, diabetes control, reduce blood pressure, 
manage lower limb osteoarthritis symptoms, manage low 
mood/depression) and by self-reported IT literacy level 
on a visual analogue scale (ie, lower or higher confi-
dence). To maintain allocation concealment, the mini-
misation procedure will retain a stochastic element and 
will be conducted using a secure, password protected 
web-based system.
blinding
The ERS practitioners should be unaware of trial partic-
ipants’ treatment allocations. Blinding of participants is 
not possible, given the nature of the intervention. Given 
that the primary outcome is an objective measure of phys-
ical activity recorded by accelerometer, and the secondary 
outcomes will be assessed by participant self-completion 
questionnaire, the risk of assessor bias is likely to be negli-
gible in this study. However, to minimise any potential 
bias, the statistical analysis will be kept blinded and the 
code for group allocation not broken until the primary 
and secondary analyses have been completed.
Follow-up
At 4 weeks post-baseline, a short survey on initial uptake 
of the ERS will be administered via email.
At 4 and 12 months post-randomisation, participants 
will be sent an accelerometer and questionnaire booklet 
by post, along with a simple instruction sheet on how to 
wear the accelerometer, and a prepaid envelope to return 
the items to the CTU.
To maximise data completeness at follow-up assess-
ments, participants will be sent standard letters/emails 
from the CTU: (i) 7 days before delivery of the acceler-
ometer, (ii) 3 days into the 10-day recording window as a 
prompt for the participant to begin wearing the acceler-
ometer (if not already doing so) and (iii) should the accel-
erometer not have been received at the CTU, at 3 and 5 
Table 1 Schedule of baseline and follow-up measures
Measure Baseline Randomisation 4 weeks 4 months 12 months
Demographics X
Objectively measured physical activity (eg, minutes of 
MVPA in ≥10 min bouts, recorded by accelerometer)
X X X
Engagement with the ERS (uptake at 4 weeks, plus 
subsequent attendance at ERS, eg, number of sessions 
attended)
X                          X
Engagement with e-coachER (captured from the 
LifeGuide platform)
X X X
Self-reported:
 ► MVPA (7-day recall of physical activity)
 ► Health and social care resource use
 ► Quality of life measures: 5-level Euroqol-5D (EQ-5D-
5L), SF-12v2
 ► Hospital Anxiety and Depression Scale
X X X
Process evaluation outcomes (eg, self-reported 
confidence to be physically active; perceived frequency 
and availability of support; perceived autonomy over 
choices; involvement in self-monitoring and planning 
physical activity)
X X X
Qualitative interviews as part of the process evaluation 
focusing on participants’ experiences with the ERS and 
the intervention (optional for participants)
————————————————X————————
—————————
ERS, exercise referral scheme; MVPA, moderate- to- vigorous physical activity.
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weeks after issue as a reminder to post the accelerometer 
to the CTU. If the participant has not sent the accelerom-
eter to the CTU after 6 weeks, the local researcher will 
telephone the participant to remind them to return the 
device. Participants who return the accelerometer to the 
CTU will receive an online/high street store voucher for 
£20 as a token ‘thank you’, to maximise response rates.
trial treatment/trial arms
Intervention: web-based support plus ERS (e-coachER)
e-coachER is a web-based support package, which offers 
a range of interactive opportunities to enhance partic-
ipants’ motivation to take up the ERS and to maintain 
a more physically active lifestyle, whether or not they 
engage with their local ERS. A logic model for the inter-
vention is shown in figure 2.
e-coachER is primarily a self-delivered intervention and 
comprises the following components:
 ► A mailed ‘Welcome Pack’ that contains a user guide 
and the participant’s unique user log-in; a simple 
pedometer (step-counter) and a notepad to record 
daily physical activity (appended to a magnet with 
study-specific branding). Participants are encouraged 
to make use of the pedometer and the activity record 
sheets for self-monitoring and goal setting in conjunc-
tion with the e-coachER website.
 ► The e-coachER website (on the LifeGuide platform). 
At the core of e-coachER are seven ‘Steps to Health’ 
lasting approximately 5–10 min each, designed to: 
encourage participants to think about the benefits 
of physical activity (motivation); seek support from 
an ERS practitioner, friends/family and the internet 
(support/relatedness); set progressive goals; self-mon-
itor physical activity with a pedometer and upload step 
counts or minutes of MVPA (self-regulation, building 
confidence/autonomy); find ways to increase physical 
activity more sustainably in the context of day-to-day 
life and deal with setbacks (building confidence). 
The sequential content, objectives and how this was 
Figure 2 Logic model for e-coachER intervention. ERS, exercise referral scheme; MVPA, moderate- to- vigorous physical 
activity.
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implemented were mapped against a taxonomy for 
behaviour change techniques30 (table 2). Self-de-
termination theory underpins the intervention with 
core aims in every step and interaction with partici-
pants, aiming to build confidence, autonomy and 
relatedness.31
Participants are encouraged to use the e-coachER 
support package as an interactive tool by using preset 
or user-defined reminders to promote ongoing use of 
functions such as recording weekly physical activity 
(minutes of MVPA) and goal setting, and receive 
messages of encouragement. Prompts are sent to 
remind participants to review their goals. An absence 
of engagement (eg, failure to review a goal, or not 
signing into the website for 1, 2 and 4 weeks) triggers 
reminder emails to the participant.
The website content will be locked prior to starting 
recruitment, with the exception of webpages 
displaying links to reputable generic websites for 
further information about the chronic conditions of 
interest and lifestyle, links to other websites and apps 
for self-monitoring health behaviour and health as 
well as modifiable listings of local opportunities to 
engage in physical activity.
An avatar is used throughout the content to avoid 
having to represent a range of individual character-
istics such as age, gender and ethnicity. The avatar 
delivers brief narratives to normalise and support 
behaviour change and encourage use of the e-coachER 
support package.
 ► To maximise accessibility and usage, a local researcher 
will provide technical support if requested. If a partici-
pant does not register on the e-coachER website within 
the first few weeks, the local researcher will contact 
the participant to offer support to register. If a partici-
pant requires technical support to resolve operational 
issues with the website (eg, requires a password to be 
reissued), participants will be referred to a centralised 
technician within the LifeGuide team.
Intervention development, including piloting the 
Welcome Pack and developing an initial version of 
e-coachER, was built on wide ranging experiences from 
the development of other self-management interventions 
using the LifeGuide platform,32 and beta-testing over 
7 months with input from service users. Co-applicants 
and researchers then provided feedback on a time-trun-
cated version of the e-coachER website, and ERS patients 
provided feedback on a real-time version, for 5 months 
before the website was locked for the randomised 
controlled trial.
Usual care
There is currently no single model for ERS in the UK, but 
the predominant modes of delivery involve referral to a 
programme (eg, 10–12 weeks) of structured, supervised 
exercise at an exercise facility (eg, gym or leisure centre) 
or a counselling approach to support patients to engage 
in a variety of types of physical activity.11 ERS operate 
diversely to accommodate patient choice and local avail-
ability of facilities, the common goal being to reduce the 
risk of long-term metabolic, musculoskeletal and mental 
health conditions due to physical inactivity. The three 
participating sites were selected from different regions of 
the UK (different ERS providers) to provide diversity of 
approach; the schemes are described in table 3.
determination of sample size
In the absence of a published minimally important 
difference for MVPA, assuming a ‘small’ to ‘moderate’ 
standardised effect size of 0.35, we estimated that 413 
participants are required at 88% power and a two-sided 
alpha of 5% assuming 20% attrition, or 90% power at a 
two-sided alpha of 5% allowing for 16% attrition (using 
‘sampsi’ in STATA V.14). Given that the intervention is 
being delivered at the level of the individual participant, 
clustering has not been factored into the sample size 
calculation. Based on the baseline SD for MVPA total 
weekly minutes in ≥10 min bouts of 104–113,33 an effect 
size of 0.35 would correspond to a between-group differ-
ence of 36–39 min of MVPA per week.
Measures
Primary outcome measure
The primary outcome is the number of weekly minutes of 
MVPA, in ≥10 min bouts, measured objectively by GENE-
Activ Original accelerometer,34 over 1 week at 12 months 
post-randomisation compared with the control group. 
To be included participants need to provide activity 
recorded over 4 days, including a weekend day, for at least 
16 hours/day.
Additional measures
 ► Total weekly minutes of MVPA in ≥10 min bouts, 
measured objectively by accelerometer, over 1 week at 
4 months.
 ► Achievement of at least 150 min of MVPA, measured 
objectively by accelerometer, over 1 week at 4 and 12 
months.
 ► Achievement of at least 150 min of MVPA over 1 week 
using the self-reported 7-day Physical Activity Recall 
Questionnaire at 4 and 12 months.
 ► Self-reported weekly minutes of MVPA at 4 and 12 
months.
 ► Average daily hours of sedentary behaviour measured 
objectively by accelerometer over 1 week at 4 and 12 
months.
 ► Self-reported average daily hours of sleep over 1 week 
at 4 and 12 months.
 ► Self-reported health-related quality of life, assessed by 
the EQ-5D-5L35and SF-12v236 at 4 and 12 months.
 ► Self-reported symptoms of anxiety and depression, 
assessed by the Hospital Anxiety and Depression 
Scale37 at 4 and 12 months.
 ► Uptake of the ERS by participant self-report at 
approximately 4 weeks and at 4 months, and from ERS 
records.
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Table 2 The e-coachER sequential process and objectives mapped against behaviour change techniques, and explanation of the implementation strategy
Sequential process Performance objectives Behaviour change techniques30 Implementation strategy
Welcome pack, pedometer 
and Introduction to web-
based support for self-
directed physical activity
To introduce the user to the philosophy of the 
website to become personal coach.
Build on personal support provided by ERS 
using web-based platform.
Support those who do not want to/cannot 
engage with ERS personnel.
Support achievement of personal goals for 
physical activity to enhance health.
10. Self-monitoring Explain philosophy of using website to become own personal coach.
Links provided to local services and other self-help resources to highlight 
patient autonomy and choice.
Offers e-coachER facilitator to help with using technology. Provide link to IT 
support from LifeGuide team.
Step 1: thinking about the 
benefits of physical activity
Elevate importance of physical activity. 82. Information about health 
consequences
83. Information about emotional 
consequences
Quiz to engage participants using positive framing.
Provide evidence of multiple benefits of physical activity, especially for 
relevant health condition(s).
Elicit and address concerns about physical activity, describing support given 
as part of ERS and by website.
Step 2: support to get 
active
To encourage user to access and create social 
support networks.
To encourage user to take advantage of ERS 
and face-to-face support offered.
1. Social support (practical)
2. Social support (emotional)
3. Social support (unspecified)
Explain how to make the most out of the ERS support to learn how to 
become own personal trainer in future.
Explain how user can create a personal ‘physical activity challenge’ and 
share it with family, friends, peers and exercise and health professionals. The 
patient may be encouraged to tell others about how e-coachER has been 
used to support behaviour change.
Suggest ways of involving family or friends in long-term support for 
continued physical activity.
Link to online sources of local support (eg, local walking or jogging group, or 
British Trust for Conservation Volunteers).
How to use website to send personalised email/text reminders, motivational 
messages to self.
Draw on positive normative beliefs; identify benefits of social interaction 
(companionship). Sharing personal physical activity challenge with others, 
involve friends and family, online local support links.
Identify benefits of informational support (from ERS) in addition to emotional 
support from family and friends.
Step 3: counting your steps To encourage and support the user to monitor 
step counts using a pedometer over a week.
Emphasise personal experimentation.
10. Self-monitoring of behaviour Provide guidance on how to count steps/use pedometer.
Provide guidance on how steps can be implemented into lifestyle.
Encourage self-monitoring using diary.
Step 4: making your step 
plans
To set explicit step count goals for the 
following week.
66. Goal setting (behaviour) Give rationale and evidence for goal-setting for graded increase in physical 
activity.
User sets specific, achievable goals for next week (eg, sessions completed, 
step count using the supplied pedometers).
Links provided to local services and other resources.
Step 5: making your activity 
plans
To encourage and support the user to identify 
behavioural goals (types of activities).
68. Action planning User selects walking or ‘other physical activities’ (which includes options for 
facility-based activity with practitioner support within ERS).
Present options for facility and lifestyle-based activity.
Sets specific, achievable goals for next week with a particular focus on 
avoiding days with less activity by planning walking or other activities.
Keeping a physical activity diary.
Continued
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Sequential process Performance objectives Behaviour change techniques30 Implementation strategy
Weekly goal and physical 
activity review
To promote adherence and graded increase in 
physical activity by providing tailored feedback 
and advice based on self-reported goal 
progress.
66. Goal setting behaviour
68. Action planning
69. Review behaviour goals
User records extent to which goals achieved in previous week, gets progress 
graph and personalised feedback.
Praise for any goal achievement, encouragement to set a more challenging 
goal if not yet meeting target physical activity criteria.
Encouragement where goals not attained, with links to webpages to assist 
with increasing motivation or confidence, selecting different activities or 
goals, making better plans, accessing support, overcoming setbacks (with 
links to relevant sessions below).
Each session completed ends with new links to reputable information and 
resources (eg, NHS choices, condition-specific physical activity advice 
websites).
Help user plan gradual increases in physical activity.
Step 6: finding ways to 
achieve your plans
To help the user harness their environment to 
provide support for physical activity.
Identifying personal motivations, building 
confidence.
30. Restructuring the physical 
environment
31. Restructuring the social 
environment
32. Avoidance/reducing exposure to 
cues for behaviour
Make plan to use environment to automatically support physical activity (eg, 
fitness equipment in living room, route to work/shops that involves more 
physical activity, committing self to specific routine).
Advise user on how to use website to send personalised email/text 
reminders, motivational messages.
Overcoming barriers in work, leisure, home and travel. Building self-efficacy.
Using smart phone apps for mobile support (eg, PowerTracker (c), 
MyFitnessPal (c)).
Invite user to identify personal motivations for becoming more active.
Motivational messages (text 
and/or emails)
To provide reminders of user's personal 
reasons (not necessarily health reasons) for 
becoming more active.
15. Prompts/cues Invite user to write motivational message to be sent weekly or monthly 
detailing their own motivations for becoming more active.
Step 7: dealing with 
setbacks
To provide strategies for overcoming relapse in 
levels of physical activity.
5. Reduce negative emotions Identify possible causes of relapse (eg, illness, holidays, change in work 
hours, new caring responsibilities) and plan ways to overcome barriers.
Challenging catastrophic negative thoughts about lapses from intended 
physical activity.
How to learn from a lapse and plan to avoid or overcome in future.
Provide salient role models of people overcoming barriers to successfully 
engage with physical activity.
ERS, exercise referral scheme. 
Table 2 Continued 
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Table 3 Characteristics of the local ERS involved in the study
South West England (predominantly Plymouth) West Midlands (Birmingham)
Greater Glasgow and Clyde (GGC) Health Board 
Area
Population of city/
locality and general 
characteristics
264 000
93% White British.
Average age is 39 years.
Plymouth has higher than average levels of poverty 
and deprivation (26.2% of population among the 
poorest 20.4% nationally).
Life expectancy, at 78.3 years for men and 82.1 for 
women, is the lowest of any region in the South 
West of England.
1 244 438
White British (53.1%), Pakistani 
(13.5%) and Indian (6%). Birmingham 
is ranked the sixth most deprived local 
authority in the UK.
Approximately 40% of the population 
lives in highly deprived areas.
The average life expectancy in 
Birmingham is 77.1 years for males and 
81.9 years for females.
1 161 370
GGC is the largest health board in the UK, comprising 
six local authority areas: 92.5% white, 5.3% Asian, 
Asian Scottish or Asian British, 1.2% African, 0.2% 
Caribbean or black, 0.4% mixed, 0.4% other.
There is large variation in deprivation across GGC, but 
as a whole, it experiences higher than average levels 
of deprivation and poverty (34.4% population among 
the poorest 12.4% national average).
Life expectancy at 74.9 years for males and 80.0 years 
for females, is the lowest in Scotland.
Number of centres/
facilities where 
referrals are made to 
in the ERS
One main ERS run by Everyone Active in Plymouth 
and two smaller ones in rural locations.
Referrals for ERS came from 31 local GP practices.
One main ERS, Be Active Plus run by 
Birmingham City Council Wellbeing 
Service.
Referrals for ERS came from 286 local 
GP practices.
One main ERS (Live Active) delivered by six local 
leisure trusts in six local authority areas of GGC 
(Glasgow, East Renfrewshire, Renfrewshire, East 
Dunbartonshire, West Dunbartonshire and Inverclyde).
Referrals are possible from any health professional in 
primary and secondary care.
Weeks, sessions and 
general details about 
ERS
Schemes vary from 6 to 12 weeks, attendees 
should commit to a minimum of two sessions/week 
in the gym with drop-in swimming, aquafit and 
gentle exercise group sessions available to all.
All ERS referrals are risk assessed as low or 
medium risk. Those classed at medium risk may 
only attend a supervised session. Additionally, a 
‘walking for health’ scheme is highlighted by one 
ERS provider.
Patients meet with a health and fitness 
advisor to discuss their preferences 
for physical activity and an individually 
tailored 12-week exercise programme 
is designed for them.
Activities include the use of gyms, 
swimming, fitness classes, badminton 
and table tennis. The gyms are local 
authority or privately owned. Privately 
owned gyms are obliged to offer their 
facilities to Be Active Plus participants. 
Patients are also told about activities 
such as the use of parks and open 
spaces in Birmingham and walking to 
work, etc.
Participants are also contacted after 
3 and 6 months and a report is sent to 
their GP at their 12-week exit interview.
Patients meet with an ERS advisor for behavioural 
change support and to design a suitable physical 
activity plan.
Patients are given information on a variety of physical 
activity options including those offered by leisure 
centres (eg, fitness classes, swimming, gym, etc) as 
well as health walks, home exercise, active travel, 
apps, etc and are able to offer specialist guidance on 
activities suitable for those with medical conditions 
and/or disabilities.
Patients assessed as high risk at referral are screened 
by a cardiologist prior to being accepted to the 
scheme.
There are fixed contact points of 1, 3, 6 and 
12 months, but patients can choose how often they 
wish support (telephone, email or face-to-face) from 
the advisor in addition to these over a 12-month 
period.
Continued
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South West England (predominantly Plymouth) West Midlands (Birmingham)
Greater Glasgow and Clyde (GGC) Health Board 
Area
Cost for patients in 
ERS (if applicable)
Costs vary related to age/concessions.
3 months ERS costs between £14.90 and £70 
inclusive of all activities. Pay as you go: £2.10–
£3.50 per session.
Patients are not charged for their 
assessment and support by the health 
and fitness advisor. The costs of 
the programme depend on chosen 
activities and leisure centre attended.
Patients in receipt of state benefits or 
tax credits are eligible for a Passport 
to Leisure which entitles them to 
a 30% discount on most activities 
offered at Birmingham City Council run 
leisure centres, well-being centres and 
swimming pools. They can attend free 
Be Active sessions which take place at 
restricted times in leisure centres.
Live Active behavioural support is free to the patient 
for 12 months.
If patients wish to use leisure facilities, they are 
entitled to access this at a concessionary rate (usually 
around 30% reduction).
Number of people 
referred to local ERS 
from 1 August 2015 
to 31 March 2017 (ie, 
during the recruitment 
period of the study)
300 3470 6500
Most common 
primary reason for 
referrals
(1 August 2015 to 31 
March 2017)*
Depression/anxiety/stress: 24% BMI>30: 28% BMI≥30: 58%
*The data on primary reason for referral are subjective as many patients have multiple conditions and a practitioner may favour recording one condition (eg, obesity) rather than another (eg, 
low mood). Within the respective schemes, the quality of recording the referral reason also appears to be variable.
BMI, body mass index; ERS, exercise referral scheme; GP, general practitioner. 
Table 3 Continued 
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 ► Adherence to physical activity, using a composite measure 
to describe the proportion in each arm of the trial that 
achieved at least 150 min of MVPA in bouts of at least 
10 min at 4 months and were still doing so at 12 months.
Self-reported survey process measures
 ► Single and multiple items, using Likert scales, to 
assess self-efficacy/confidence to be physically active, 
importance of being physically active, relatedness 
(perceived frequency and availability of support), 
perceived autonomy/control over physically active 
choices, involvement in self-monitoring and planning 
to do physical activity.
 ► In the intervention group, measures of engagement 
with e-coachER including whether or not the partici-
pant visits the website at least once, and whether they 
reach a stage of the online support to indicate they 
have set and reviewed at least one physical activity 
goal. Experience from engagement with other Life-
Guide online interventions suggests there may not be 
an optimum dose of engagement.
Economic evaluation
 ► Cost-effectiveness. Incremental cost of the interven-
tion to the NHS and incremental cost per change in 
minutes of MVPA (in ≥10 min bouts) and per QALY.
 ► An economic evaluation of e-coachER will be under-
taken using NHS, personal social services, and patient 
perspective. The analysis will be twofold—short-term 
(within-trial) cost-effectiveness analysis (from base-
line to 12 months postrandomisation) and long-term 
cost-effectiveness analysis (beyond-trial modelling 
of long-term expectations for cost-effectiveness), for 
e-coachER against ERS. The main outcome of the 
economic analysis will be an incremental cost per 
QALY (based on EQ-5D-5L). The short-term cost-ef-
fectiveness analysis will use resource use data for 
development of training of and input from a local 
LifeGuide facilitator, and central LifeGuide techni-
cian; provision and running of the exercise sessions at 
leisure centres and health and personal social service 
use. Data will be collected using the e-coachER moni-
toring system, key informant interviews (including 
trial manager), review of trial management records 
and participants’ questionnaires at baseline, 4 and 12 
months. Unit costs will be taken from the NHS refer-
ence costs (eg, DH 2015/2016),38 standard unit costs39 
and published literature. The long-term cost-effective-
ness of e-coachER will be based on an existing poli-
cy-relevant decision analytical model.40 41 The analysis 
will account for the impact of physical activity on life-
time risk of developing coronary heart disease, stroke 
and type 2 diabetes.
Process evaluation
The barriers to, and facilitators for, recruitment will be 
explored with participants in the early stages of the trial 
through qualitative interviews with local researchers 
at each site, and also via local researcher field notes of 
conversations with participants at various stages of the 
trial. Along with relevant supporting literature, this infor-
mation will be used to optimise recruitment during the 
remainder of the trial.
Following guidelines for evaluating complex interven-
tions,42 a nested mixed methods process evaluation will 
be undertaken, focussing on identifying factors relating to 
recruitment, engagement, acceptability, mechanisms and 
fidelity.
The assessment of barriers and facilitators in recruit-
ment will involve the following:
1. Interviews with researchers about patient-reported rea-
sons for joining the study or not;
2. Interviews with researchers about barriers to recruit-
ment in the primary care setting, and among exercise 
referral practitioners.
The logic model shown in figure 2 will guide the process 
evaluation of the intervention. The logic model shows the 
types of data that will be collected, as well as the causal 
pathways proposed to contribute to behaviour change 
and intervention outcomes.
The assessment of intervention engagement and 
acceptability will involve the following:
1. Semi-structured interviews with up to 10% of the in-
tervention group participants. A purposeful sampling 
framework will be used to ensure participants with 
a range of characteristics (gender, age, underlying 
health condition and trial centre) are invited to take 
part. Interviews will be conducted at different stages 
of participation in the trial, with each individual be-
ing invited to participate in telephone interviews 
and if appropriate follow-up interviews (up to a max-
imum of three telephone interviews over the course 
of the intervention period (approximately 4 months). 
Interviews will be recorded and transcribed and per-
sonal data or ways of identifying participants removed. 
Transcriptions will be imported into NVivo for data 
management purposes. The interview transcripts will 
be coded and thematic analysis performed to iden-
tify key findings. Analysis will initially focus on ‘top 
level’ themes, reflected in the intervention logic mod-
el. Analysis will follow the principles of Framework 
Analysis.43 Further in-depth analysis will also be un-
dertaken in order to ensure emergent data, for ex-
ample, from longitudinal cases, or condition-specific 
themes, are explored fully. The focus of the interview 
questions will be linked to the phase of the interven-
tion, and seek to identify the perceived value of the 
‘Welcome Pack’ and contents in helping to access 
e-coachER, the overall web-based support and each 
of the Steps to Health, in terms of functionality and 
utility to support behaviour change. Participants will 
be asked to identify if and how they thought e-coach-
ER provided support for their ERS, and maintaining 
physical activity in addition to and beyond the ERS 
support. Ideas for additions or revisions to e-coach-
ER will be requested. Questions will also focus on the 
H
e
n
d
e
rs
o
n
-L
ib
 &
 M
e
d
ia
 S
e
r. P
ro
te
c
te
d
 b
y
 c
o
p
y
rig
h
t.
 o
n
 D
e
c
e
m
b
e
r 2
3
, 2
0
1
9
 a
t U
n
iv
e
rs
ity
 o
f P
ly
m
o
u
th
 - L
ib
ra
ry
 A
.
h
ttp
://b
m
jo
p
e
n
.b
m
j.c
o
m
/
B
M
J
 O
p
e
n
: firs
t p
u
b
lis
h
e
d
 a
s
 1
0
.1
1
3
6
/b
m
jo
p
e
n
-2
0
1
8
-0
2
2
3
8
2
 o
n
 2
1
 S
e
p
te
m
b
e
r 2
0
1
8
. D
o
w
n
lo
a
d
e
d
 fro
m
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Br J Sports Med
 doi: 10.1136/bjsports-2020-103121–8.:10 2020;Br J Sports Med, et al. Taylor A
13Ingram W, et al. BMJ Open 2018;8:e022382. doi:10.1136/bmjopen-2018-022382
Open access
participants’ perceived development of self-regulatory 
skills (eg, self-monitoring, goal setting) and the extent 
to which the intervention enhanced a sense of compe-
tence, autonomy and relatedness, thereby linking back 
to the aims and guiding principles of the e-coachER 
intervention.
2. The researchers will be asked to maintain field notes 
on any interactions with participants concerning en-
gagement with the intervention, such as any difficul-
ties faced with accessing the intervention website. 
Semi-structured interviews will be conducted by the 
qualitative researcher with the researchers at each re-
cruitment site to identify participant barriers and facil-
itators to using e-coachER.
3. Engagement with the web-based e-coachER support 
system will be quantified. Metrics such as whether 
the participant registered, how far they progressed in 
the seven Steps to Health, visits to and time spent on 
different web pages and within each of the respective 
Steps, number of times step counts or amount of phys-
ical activity (eg, MVPA) were entered into e-coachER 
(ie, self-monitoring) and number of times goals were 
achieved and reviewed.
4. Changes in the process measures (see above) (eg, 
self-efficacy/confidence to be and importance of be-
ing physically active) from baseline to 4 and 12 months 
follow-up will be assessed and compared between in-
tervention arms.
5. Mediation analysis to determine the extent to which 
changes in the process measures mediate the effect 
of the intervention on changes in physical activity at 4 
and 12 months.
data handling
Data will be collected and stored in accordance with the 
Data Protection Act 1998/General Data Protection Regu-
lation 2018.
Subject numbering
Following receipt of expression of interest, each patient 
will be allocated a unique number and will then be identi-
fied in all study-related documentation by their identifi-
cation number and initials. A record of names, addresses, 
telephone numbers and email addresses linked to partic-
ipants’ identification numbers will be stored securely 
on the study database for administrative purposes 
only.
Data collection
Data will be recorded on study-specific paper-based case 
report forms (CRFs) by the local researcher, and partici-
pants will complete a paper-based questionnaire booklet 
comprising validated and non-validated self-report 
outcome measures (listed in table 1).
Accelerometers will be configured for use prior to issue 
to participants by the local researcher at baseline and the 
CTU thereafter, using GENEActiv software. A recording 
window of 10 days, recording at 75 Hz, will be preset, thus 
accounting for transits in the post while optimising the 
battery life of the device.
Accelerometers received by the CTU following 1 weeks’ 
wear by the participant will be physically cleaned with 
liquid detergent (according to manufacturer’s instruc-
tions) before data are downloaded via GENEActiv soft-
ware and linked to participant identification number. 
Accelerometers will then be issued to other participants 
in the trial as required.
Data on participants’ uptake of the ERS will be collected 
via a single use token-based authenticated email sent to 
participants at 4 weeks post-baseline. This will be a short 
survey requesting information on whether the participant 
has attended the initial consultation with the ERS advisor, 
and predefined reasons for non-attendance status, for 
example, appointment has been booked but not yet 
attended.
All persons authorised to collect and record study data 
at each site will be listed on the study site delegation logs, 
signed by the Principal Investigator.
Data entry
Original CRFs and questionnaire booklets will be posted 
to the CTU, with copies of the CRF retained at the study 
site. All data will be double-entered by CTU staff on to a 
password-protected SQL Server database and encrypted 
using Secure Sockets Layer. Double-entered data will be 
compared for discrepancies using a stored procedure and 
discrepant data will be verified using the original CRF. 
Incomplete, incoherent, unreadable or other problem 
data in the CRF pages will be queried by the CTU with 
study site staff during data entry to ensure a complete 
and valid dataset. Self-reported data in the questionnaire 
booklet will not be queried with participants.
The CTU may complete further validation of data 
items, perform logical data checks and raise further data 
queries after data collection has been completed. The 
final export of anonymous data will be transferred to 
statisticians for analysis after all data cleaning duties have 
been performed by the CTU.
data analysis plan
All analyses will be carried out using a detailed a priori 
statistical analysis plan. Analyses will be reported in full 
and in accordance with the  Consolidated Standards of 
Reporting Trials (CONSORT) guidelines.44 Recruitment, 
uptake of the ERS, engagement with the intervention, 
outcome completion rates and study withdrawal will be 
reported (with 95% CIs). Baseline characteristics in the 
two trial arms will be reported.
The primary analysis will compare complete case outcomes 
between intervention and control arms groups according to 
the principle of intention to treat (ie, according to original 
randomised allocation) at 12 months adjusting for baseline 
outcome values and stratification and minimisation variables 
(recruitment site and disease indication).
Secondary analyses will be undertaken to compare 
groups at follow-up across all follow-up points (ie, 4 and 
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12 months) using a mixed effects repeated measures 
approach. In addition, we will seek to undertake 
secondary per-protocol analyses using a complier average 
causal effect approach to examine the impact of different 
levels of the adherence to the intervention.
Accelerometry data will be analysed with bespoke soft-
ware to classify data into levels of physical activity intensity 
using accepted cut-points. Standard operating proce-
dures will be applied to make a decision about dealing 
with missing data.
The primary analysis model will be extended to fit inter-
action terms to explore possible subgroup differences 
in intervention effect in stratification and minimisation 
variables and the predefined baseline characteristics. As 
not formally powered, these subgroup analyses will be 
regarded as exploratory and hypothesis-generating.
Sensitivity analysis, using multiple imputation and 
assuming unobserved measurements are missing at 
random will be conducted for both primary and secondary 
analyses to assess the likely impact of missing data on the 
primary and secondary outcomes at 12 months. Contem-
porary mediational analysis methods45 will be used to 
explore the impact of process outcomes identified in the 
planned intervention components, including engage-
ment, use of behaviour change techniques and motiva-
tion and processes of change (eg, self-efficacy, autonomy, 
relatedness).
No interim analysis of primary or secondary outcomes 
is planned. No adjustment of p-values will be made to 
account for multiple testing, although the implications of 
multiple testing will be considered when evaluating the 
results of the analyses. Analysis of the primary outcome 
will be performed prior to all other analyses. All analyses 
will be undertaken using STATA V.14.2.
Checks will be undertaken to assess the robustness of 
models, including assessment of model residual normality 
and heteroscedasticity.
Patient and public involvement
The research question was informed by patient and 
public involvement (PPI) over many years. Individual and 
group interviews were conducted with patients to identify 
the barriers and facilitators associated with ERS, and what 
additional support could help maintain physical activity 
for a variety of chronic conditions. Our extensive engage-
ment with ERS practitioners allowed us to understand the 
individual variability and collective patient experience 
of ERS. This included one of the authors developing, 
delivering and adapting a training course for ERS practi-
tioners based on their feedback.
The LifeGuide team worked extensively with PPI 
representatives to develop the appropriate support, 
concluding that ERS patients would appreciate additional 
support from an ERS to help them to further develop the 
independent motivation to maintain physical activity, 
involving a broad range of active options. Also, patients 
widely indicated that the LifeGuide web-based system 
can provide appropriate support for making health 
behaviour changes. Typically ERS can increase health 
inequalities by limiting access to those who have limited 
disposable income or have restricting physical and mental 
health conditions. The e-coachER system was designed to 
support those with such restrictions.
Patients were involved in the design of the study. A PPI 
group was involved in the initial development and refine-
ment of the e-coachER web-based behavioural support. 
Patients with experience of being referred for an exer-
cise programme, took part in focus groups and provided 
direct feedback on iterations of the e-coachER interven-
tion during its development.
We engaged with over 20 ERS patients who volunteered 
to pilot the e-coachER Welcome Pack and provide feed-
back on the e-coachER website. A PPI representative was 
available to provide opinions on the study protocol and 
patient-facing documentation (eg, Participant Informa-
tion Sheet) during the set-up of the study.
Patients are involved in the oversight of study prog-
ress and conduct via representation at periodic Project 
Management Group meetings and Trial Steering 
Committee meetings.
Results will be disseminated to study participants. 
At the end of the trial, a plain English summary of the 
study results will be made available to participants via a 
designated webpage on the Peninsula Clinical Trials Unit 
website, and emailed or posted to participants on request.
trial monitoring and oversight
A Project Management Group including the Chief Inves-
tigator, Principal Investigators, co-applicants, CTU Trial 
Manager, ERS advisor and PPI representative will meet 
quarterly to provide multidisciplinary input and oversight 
for the study.
A Trial Steering Committee (TSC) including an inde-
pendent chair, independent clinicians and/or academics 
with relevant expertise, independent statistician/meth-
odologist with relevant expertise and a representative 
contributing a patient/public perspective will oversee 
the conduct and scientific integrity of the trial. The TSC 
will review study progress and protocol adherence. Each 
committee will function in accordance with agreed terms 
of reference set out in a charter.
An independent Data Monitoring Committee (DMC) 
will monitor the safety and ethics of the trial by over-
seeing recruitment, primary outcome data completeness 
and serious adverse event data.
The committees will meet once before the start of the 
trial and approximately annually thereafter.
EthICs And dIssEMInAtIon
safety considerations
The recording and reporting of non-serious adverse 
events in this study will not be required. Serious adverse 
events (SAE) will be captured via survey-specific items on 
hospital admissions in the questionnaire booklet at 4 and 
12 months, that is, reason and duration of the inpatient 
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stay, and self-reported relatedness of the SAE to partici-
pation in the trial; self-report independent of the ques-
tionnaire booklet; notification to the local researcher by 
the participant’s relative/advocate or notification by the 
participant’s GP.
Reports of SAEs will be provided to the CTU. The CTU 
will liaise with the local researcher who will be responsible 
for ascertaining further details about the SAE as appro-
priate. The Chief Investigator will report any SAE that is 
related (definitely, possibly or probably related) to the 
research procedures to the Research Ethics Committee 
within 15 days of becoming aware of the event. The CTU 
will prepare quarterly summaries of SAEs for review by 
the independent DMC and Sponsor.
dissemination plan
The findings of the study will be made publicly available 
through publication in relevant peer-reviewed journals 
and the NIHR Journals Library website; and presenta-
tion to the scientific community, patient support groups, 
the ERS services and NHS strategy forums at local and 
national level. The study is reported in accordance with 
CONSORT guidelines for publishing randomised trials 
and TIDieR guidelines for intervention reporting.
A plain English summary of the main study results will be 
made available for participants and other lay audiences.
Changes to the protocol after the start of the trial
Primary outcome measure and sample size
The original protocol featured an internal pilot. During 
the internal pilot phase, 180 patients were to be recruited 
over 3 months to provide sufficient information to justify 
progression to a main trial. Progression from the internal 
pilot to the main trial was dependent on recruitment rate 
and engagement with the intervention according to the 
scenarios in table 4. In the main trial, an additional 1220 
participants were to be recruited, giving a total of 1400 
participants (recruited over 16 months).
The recruitment rate during the internal pilot phase 
was lower than expected, due to limitations on the time 
primary care practitioners had available to approach 
potential participants; delayed start at one of the research 
sites; poor uptake when patients were approached via a 
postal mailshot; high ineligibility rate among patients who 
were identified via a primary care database. In response 
to poor recruitment, the following strategies to increase 
recruitment were introduced:
 ► The inclusion criterion for BMI was aligned with the 
ERS entry (upper BMI limit for the trial was originally 
35 and was raised to 40), and prediabetes was included 
as an inclusion criterion.
 ► Recruitment via the ERS service, which was already 
taking place at the site in Greater Glasgow, was 
adopted in the West Midlands and the South West in 
addition to recruitment via primary care.
 ► Incentive payments to participants (for returning an 
accelerometer) were increased from £10 to £20 per 
accelerometer.
Having implemented these measures, the conditions 
for progression in terms of recruitment rate and engage-
ment with the intervention were not met by the end of the 
internal pilot phase, despite a 4-month extension period. 
A ‘recovery plan’ was developed in collaboration with 
the funders, based on amending the choice of primary 
outcome, and submitted in May 2016.
The original primary outcome was achievement of at 
least 150 min of MVPA measured objectively by acceler-
ometer over 1 week at 12 months. This outcome was based 
on the findings of a systematic review of ERS12 46 demon-
strating that trials had primarily reported their outcomes 
according to percentage of participants reaching the 
National Institute for Health and Care Excellence guide-
lines for physical activity level, that is, 150 min of MVPA 
per week. We estimated that recruiting 700 participants 
per group would allow us to detect a difference at 12 
months follow-up of at least 10% (intervention group: 
53% vs control group: 43%), assuming an attrition rate of 
20% and small effect of clustering (intracluster correla-
tion coefficient ICC: 0.006) at 90% power and 5% alpha. 
Thus, the original sample size was 1400 participants, to be 
recruited over 16 months.
From the outset, the TSC and DMC had recommended 
that this dichotomous primary outcome measure be 
replaced with a continuous variable; total weekly minutes 
of MVPA. This was because:
a. A continuous primary outcome measure would be 
more relevant in this study population, in terms of 
detecting a small but clinically significant increase in 
minutes of MVPA.
Table 4 Internal pilot to main trial progression rules
Criteria Scenario 3 Scenario 2 Scenario 1
% of internal pilot sample size target (180 patients) 
recruited
<65% 65%–79% ≥80%
Intervention engagement
(% participants who access e-coachER at least 
once)
<65% 65%–79% ≥80%
Proposed action No progression Discuss with Trial Steering 
Committee and funder about 
progression and resources 
needed to achieve target.
Proceed to full trial.
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b. Based on sample size calculations, this would offer 
greater statistical power than to the categorical as-
sessment of whether participants reach a threshold of 
150 min of MVPA. This would therefore afford a reduc-
tion in sample size.
The TSC and funders agreed these changes (in August 
2016) and the original sample size was reduced in accord-
ance with this new primary outcome measure and revised 
sample size calculation, from 1400 to 413 participants 
(to be recruited over 21 months). A similar reduction in 
sample size has been incorporated into the qualitative 
component of the process evaluation work.
Current study status
The e-coachER trial began recruiting patients in August 
2015 and closed to recruitment in March 2017. Data 
collection is expected to be completed in March 2018 
and results are expected to be published in September 
2018.
Author affiliations
1Faculty of Medicine and Dentistry, Peninsula Medical School, University of 
Plymouth, Plymouth, UK
2University of Exeter Medical School, Exeter, UK
3Department of Clinical Sciences, Brunel University, London, UK
4Faculty of Medicine, Southampton University, Southampton, UK
5Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK
6School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, 
Birmingham, UK
7Physical Activity for Health Research Centre, University of Edinburgh, Edinburgh, UK
8Faculty of Sport and Health, University of St Mark and St John, Plymouth, UK
9Patient & Public Involvement, Plymouth, UK
10Department of Rheumatology, Royal Cornwall Hospitals NHS Trust, Truro, UK
Acknowledgements The authors would like to thank all the patients and staff 
who are participating in the trial and also to the members of the Trial Steering 
Committee and Data Monitoring Committee for their valuable support throughout 
the lifetime of the research. The authors would like to acknowledge the role of 
the Clinical Research Network in connection with data collection and also the 
contribution made by the Department of Health and the Greater Glasgow Health 
Board in meeting the excess treatment and service support costs associated 
with the trial. In memory of Nigel Charles, with thanks for his contribution to the 
qualitative research. 
Collaborators Trial Steering Committee Full members: Dr Sharon Simpson, Chair 
(University of Glasgow); Professor Charlie Foster, Independent Member (University 
of Oxford then University of Bristol); Dr Mark Kelson, Independent Member 
(Cardiff University then University of Exeter); Professor John Powell, Independent 
Member (University of Oxford); Mr Chris Cavanagh, Patient and Public Involvement 
Representative; Professor Adrian Taylor, Chief Investigator (University of Plymouth) 
Observers; Professor Rod Taylor, Trial Statistician (University of Exeter); Dr Wendy 
Ingram, Trial Manager (Peninsula Clinical Trials Unit, University of Plymouth); Mrs 
Pam Baxter, Sponsor Representative (University of Plymouth) Data Monitoring 
Committee members; Professor Paul Aveyard (University of Oxford); Dr Anne Haase 
(University of Bristol); Professor Richard Morris (University of Bristol).
Contributors AHT conceived the idea for the study with RST, NM, KJ, LY, NA, JLC, 
CG, SGD, PL, AW/JE, BJ, JLC and RBJ. AHT, RHT, NM, KJ, LY, NA, JLC, CG, JV, SGD, 
CM, PL, JE, BJ, JLC, AW, RBJ, WI and DW contributed to the final study design and 
development of the protocol. AHT, JDL, MS and LY developed the web-support and 
led PPI testing and feedback with JK. NA developed the health economics plan. 
SGD developed the process evaluation plan with CG, NC and RHT. RHT provided the 
statistical plan. All authors critically revised successive drafts of the manuscript and 
approved the final version.
Funding This research has been conducted independently by the University 
of Plymouth, University of Birmingham, Brunel University London, University of 
Edinburgh, University of Exeter, University of Southampton, Royal Cornwall Hospitals 
NHS Trust and University of St Mark and St John. It is funded by the Department 
of Health (DH) as part of the National Institute for Health Research (NIHR) Health 
Technology Assessment (HTA) programme (project number 13/25/20). 
disclaimer The views expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health. 
Competing interests SGD reports personal fees from University College London 
outside the submitted work. CM reports grants from NIHR during the conduct of the 
study; grants from ESRC Impact Acceleration Award outside the submitted work; is 
an employee of the Health Improvement Team (NHS Greater Glasgow & Clyde) who 
fund and manage the Service Level Agreement for the Exercise Referral Scheme. 
NM reports grants from various research funders including NIHR during the conduct 
of the study. LY reports grants from NIHR during the conduct of the study. 
Patient consent Not required.
Ethics approval The original study and subsequent amendments were approved 
by the NHS Research Ethics Committee North West-Preston (REC reference 15/
NW/0347).
Provenance and peer review Commissioned bid 13/25 Interventions to enhance 
engagement in exercise referral schemes. 
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
rEFErEnCEs
 1. Public Health England. Physical inactivity: economic costs to NHS 
clinical commissioning groups London: Her Majesty's Stationery 
Office, 2016.
 2. Department of Health. Start Active, Stay Active: A report on physical 
activity from the four home countries’ Chief Medical Officers. 
London: Department of Health, 2011.
 3. NICE. Obesity: Guidance on the prevention, identification, 
assessment and management of overweight and obesity in adults 
and children. London: National Clinical Guideline Centre, 2010.
 4. NICE. Hypertension: Clinical management of primary hypertension in 
adults. London: National Clinical Guideline Centre, 2011.
 5. NICE. Type 2 diabetes: The management of type 2 diabetes. London: 
National Clinical Guideline Centre, 2008.
 6. NICE. Osteoarthritis: The care and management of osteoarthritis in 
adults. London: National Clinical Guideline Centre, 2008.
 7. NICE. Depression: The treatment and management of depression in 
adults. London: National Clinical Guideline Centre, 2009.
 8. Bouchard C, Blair SN, Katzmarzyk PT, et al. Less sitting, more 
physical activity, or higher fitness? Mayo Clin Proc 2015;90:1533–40.
 9. Warburton DE, Bredin SS. Reflections on physical activity and health: 
what should we recommend? Can J Cardiol 2016;32:495–504.
 10. Dunstan DW, Daly RM, Owen N, et al. Home-based resistance 
training is not sufficient to maintain improved glycemic control 
following supervised training in older individuals with type 2 diabetes. 
Diabetes Care 2005;28:3–9.
 11. British Heart Foundation National Centre for Physical Activity 
and Health. Section 2: A Snapshot of ER Schemes Operating in 
England, Scotland & Northern Ireland - 2006-2008: A Toolkit for the 
Design, Implementation & Evaluation of Exercise Referral Schemes: 
Loughborough University, 2010.
 12. Pavey TG, Taylor AH, Fox KR, et al. Effect of exercise referral 
schemes in primary care on physical activity and improving 
health outcomes: systematic review and meta-analysis. BMJ 
2011;343:d6462.
 13. Pavey T, Taylor A, Hillsdon M, et al. Levels and predictors of exercise 
referral scheme uptake and adherence: a systematic review. J 
Epidemiol Community Health 2012;66:737–44.
 14. Rouse PC, Ntoumanis N, Duda JL, et al. In the beginning: role of 
autonomy support on the motivation, mental health and intentions 
of participants entering an exercise referral scheme. Psychol Health 
2011;26:729–49.
 15. Joseph RP, Durant NH, Benitez TJ, et al. Internet-Based Physical 
Activity Interventions. Am J Lifestyle Med 2014;8:42–67.
 16. Devi R, Singh SJ, Powell J, et al. Internet-based interventions for the 
secondary prevention of coronary heart disease. Cochrane Database 
Syst Rev 2015;12:Cd009386.
H
e
n
d
e
rs
o
n
-L
ib
 &
 M
e
d
ia
 S
e
r. P
ro
te
c
te
d
 b
y
 c
o
p
y
rig
h
t.
 o
n
 D
e
c
e
m
b
e
r 2
3
, 2
0
1
9
 a
t U
n
iv
e
rs
ity
 o
f P
ly
m
o
u
th
 - L
ib
ra
ry
 A
.
h
ttp
://b
m
jo
p
e
n
.b
m
j.c
o
m
/
B
M
J
 O
p
e
n
: firs
t p
u
b
lis
h
e
d
 a
s
 1
0
.1
1
3
6
/b
m
jo
p
e
n
-2
0
1
8
-0
2
2
3
8
2
 o
n
 2
1
 S
e
p
te
m
b
e
r 2
0
1
8
. D
o
w
n
lo
a
d
e
d
 fro
m
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Br J Sports Med
 doi: 10.1136/bjsports-2020-103121–8.:10 2020;Br J Sports Med, et al. Taylor A
17Ingram W, et al. BMJ Open 2018;8:e022382. doi:10.1136/bmjopen-2018-022382
Open access
 17. Davies CA, Spence JC, Vandelanotte C, et al. Meta-analysis of 
internet-delivered interventions to increase physical activity levels. Int 
J Behav Nutr Phys Act 2012;9:52.
 18. Morrison LG, Hargood C, Lin SX, et al. Understanding usage of 
a hybrid website and smartphone app for weight management: a 
mixed-methods study. J Med Internet Res 2014;16:e201.
 19. Lloyd S, Dennison L, Morrison L, et al. Losing weight online with 
POWeR: a randomised controlled trial of a web-based behavioural 
intervention in a community setting. The Lancet 2013;382:S62.
 20. Williams S, Yardley L, Wills GB. A qualitative case study of LifeGuide: 
users' experiences of software for developing Internet-based 
behaviour change interventions. Health Informatics J 2013;19:61–75.
 21. Yardley L, Morrison LG, Andreou P, et al. Understanding reactions to 
an internet-delivered health-care intervention: accommodating user 
preferences for information provision. BMC Med Inform Decis Mak 
2010;10:52.
 22. Little P, Stuart B, Hobbs FR, et al. An internet-based intervention with 
brief nurse support to manage obesity in primary care (POWeR+): 
a pragmatic, parallel-group, randomised controlled trial. Lancet 
Diabetes Endocrinol 2016;4:821–8.
 23. Greaves CJ, Sheppard KE, Abraham C, et al. Systematic review 
of reviews of intervention components associated with increased 
effectiveness in dietary and physical activity interventions. BMC 
Public Health 2011;11:119.
 24. Michie S, Abraham C, Whittington C, et al. Effective techniques in 
healthy eating and physical activity interventions: a meta-regression. 
Health Psychol 2009;28:690–701.
 25. Anokye NK, Trueman P, Green C, et al. The cost-effectiveness of 
exercise referral schemes. BMC Public Health 2011;11:954.
 26. Benaissa M, Malik B, Kanakis A, et al. Tele-healthcare for diabetes 
management: A low cost automatic approach: Conference 
proceedings: Annual International Conference of the IEEE 
Engineering in Medicine and Biology Society IEEE Engineering in 
Medicine and Biology Society Annual Conference, 2012:1290–3.
 27. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: 
defining standard protocol items for clinical trials. Ann Intern Med 
2013;158:200–7.
 28. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of 
interventions: template for intervention description and replication 
(TIDieR) checklist and guide. BMJ 2014;348:g1687.
 29. Ahmad S, Harris T, Limb E, et al. Evaluation of reliability and 
validity of the General Practice Physical Activity Questionnaire 
(GPPAQ) in 60-74 year old primary care patients. BMC Fam Pract 
2015;16:113.
 30. Michie S, Richardson M, Johnston M, et al. The behavior change 
technique taxonomy (v1) of 93 hierarchically clustered techniques: 
building an international consensus for the reporting of behavior 
change interventions. Ann Behav Med 2013;46:81–95.
 31. Deci EL, Ryan RM. Handbook of self-determination research. 
Rochester, New York: University of Rochester Press, 2002.
 32. Yardley L, Morrison L, Bradbury K, et al. The person-based approach 
to intervention development: application to digital health-related 
behavior change interventions. J Med Internet Res 2015;17:e30.
 33. Harris T, Kerry SM, Victor CR, et al. A primary care nurse-delivered 
walking intervention in older adults: PACE (pedometer accelerometer 
consultation evaluation)-Lift cluster randomised controlled trial. PLoS 
Med 2015;12:e1001783.
 34. Powell C, Carson BP, Dowd KP, et al. Simultaneous validation of 
five activity monitors for use in adult populations. Scand J Med Sci 
Sports 2017;27:1881–92.
 35. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary 
testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life 
Res 2011;20:1727–36.
 36. Ware JE, Kosinski M, Turner-Bowker DM, et al. How to score version 
2 of the SF-12 health survey (with a supplement documenting version 
1). Lincoln, RI; Boston, Mass: QualityMetric Inc; Health Assessment 
Lab, 2002.
 37. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. 
Acta Psychiatr Scand 1983;67:361–70.
 38. Department of Health. NHS Reference Costs 2014 to 2015, 2015.
 39. Curtis LA. Unit costs for health and social care University of Kent. 
Canterbury: Personal Social Services Research Unit, 2014.
 40. Anokye NK, Lord J, Fox-Rushby J. Is brief advice in primary care 
a cost-effective way to promote physical activity? Br J Sports Med 
2014;48:202–6.
 41. Campbell F, Holmes M, Everson-Hock E, et al. A systematic review 
and economic evaluation of exercise referral schemes in primary 
care: a short report. Health Technol Assess 2015;19:1–110.
 42. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex 
interventions: Medical Research Council guidance. London: MRC 
Population Health Science Research Network, 2014.
 43. Ritchie J, Spencer L. Qualitative data analysis for applied policy 
research. Analysing Qualitative Data. London: Routledge, 1994.
 44. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: 
updated guidelines for reporting parallel group randomised trials. 
BMJ 2010;340:c332.
 45. Emsley R, Dunn G, White IR. Mediation and moderation of treatment 
effects in randomised controlled trials of complex interventions. Stat 
Methods Med Res 2010;19:237–70.
 46. Pavey TG, Anokye N, Taylor AH, et al. The clinical effectiveness and 
cost-effectiveness of exercise referral schemes: a systematic review 
and economic evaluation. Health Technol Assess 2011;15:1–254.
H
e
n
d
e
rs
o
n
-L
ib
 &
 M
e
d
ia
 S
e
r. P
ro
te
c
te
d
 b
y
 c
o
p
y
rig
h
t.
 o
n
 D
e
c
e
m
b
e
r 2
3
, 2
0
1
9
 a
t U
n
iv
e
rs
ity
 o
f P
ly
m
o
u
th
 - L
ib
ra
ry
 A
.
h
ttp
://b
m
jo
p
e
n
.b
m
j.c
o
m
/
B
M
J
 O
p
e
n
: firs
t p
u
b
lis
h
e
d
 a
s
 1
0
.1
1
3
6
/b
m
jo
p
e
n
-2
0
1
8
-0
2
2
3
8
2
 o
n
 2
1
 S
e
p
te
m
b
e
r 2
0
1
8
. D
o
w
n
lo
a
d
e
d
 fro
m
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Br J Sports Med
 doi: 10.1136/bjsports-2020-103121–8.:10 2020;Br J Sports Med, et al. Taylor A
  
 
  
 
 
 
 
 
A multicentre randomised controlled trial of an augmented exercise 
referral scheme using web-based behavioural support in individuals with 
metabolic, musculo-skeletal and mental health conditions 
 
 
 
STUDY PROTOCOL 
 
Version 6.1 20th November 2017 
 
 
 
  
 
 
 
 
 
 
Chief Investigator: Prof Adrian Taylor 
Professor of Health Services Research, University of Plymouth 
Study Sponsor: University of Plymouth 
IRAS reference: 170179 
REC reference: 15/NW/0347 
ISRCTN: 15644451 
Funder’s number: 13/25/20 (NIHR HTA) 
 
 
This protocol has regard for the HRA guidance
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Br J Sports Med
 doi: 10.1136/bjsports-2020-103121–8.:10 2020;Br J Sports Med, et al. Taylor A
 
e-coachER Protocol_Version 6.1 20.11.2017 
IRAS No. 170179 
REC: 15/NW/0347 ISRCTN15644451    E001 Page 1 of 39  
 
SIGNATURE PAGE 
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Investigator agrees to conduct the trial in compliance with the approved protocol and will adhere to the 
principles outlined in GCP guidelines, the Sponsor’s SOPs, and other regulatory requirements as 
amended. 
I agree to ensure that the confidential information contained in this document will not be used for any 
other purpose other than the evaluation or conduct of the clinical investigation without the prior written 
consent of the Sponsor. 
I also confirm that I will make the findings of the study publically available through publication or other 
dissemination tools without any unnecessary delay and that an honest accurate and transparent 
account of the study will be given; and that any discrepancies from the study as planned in this 
protocol will be explained. 
 
 
For and on behalf of the Study Sponsor: 
 
Signature: .................................................................................... 
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STUDY SUMMARY 
 
Study title A multicentre RCT of an augmented exercise referral scheme (ERS) using web-based 
behavioural support in individuals with metabolic, musculo-skeletal and mental health 
conditions. 
Short title e-coachER – adding web-based support to an exercise referral scheme. 
Trial design Multi-centre, individually randomised, two arm trial with internal pilot. 
Trial participants Inactive individuals aged 16-74 years with obesity, hypertension, pre-diabetes,  type 2 
diabetes, osteoarthritis, or a history of depression, for whom NICE recommends exercise. 
Planned sample 
size 
413 participants (206 per trial arm) 
Planned study 
period 
 
45 months (set up 8 months, main recruitment 19 months, follow up 12 months, data 
cleaning, analysis and reporting 6 months) 
Grant start date 01 January 2015 
Study aim To determine whether the addition of a web-based support package to usual ERS 
increases the minutes of moderate to vigorous intensity physical activity (MVPA) at twelve 
months, compared with ERS alone, and whether such an intervention is cost-effective. 
Primary outcome 
measure 
 
Total weekly minutes of MVPA in >10 minute bouts, recorded objectively by 
accelerometer, over one week at twelve months. 
Secondary 
outcome measures 
 
 Total weekly minutes of MVPA in ≥10 minute bouts, recorded objectively by 
accelerometer, over one week at four months. 
 Achievement of at least 150 minutes of MVPA, measured objectively by 
accelerometer, over one week at four and twelve months post-randomisation. 
 Average minutes of MVPA, measured by accelerometer over one week at 4 and 12 
months post-randomisation. 
 Self-reported achievement of at least 150 mins of MVPA over one week using the 
Seven Day Physical Activity Recall Questionnaire at four and twelve months.Self-
reported health-related quality of life, assessed by the EuroQol-5 dimension–5 level 
(EQ-5D-5L) and 12-Item Short Form Health Survey version 2 (SF12v2) at four and 
twelve months. 
 Self-reported symptoms of anxiety and depression, assessed by the Hospital Anxiety 
and Depression Scale (HADS) at four and twelve months. 
 Average daily hours/minutes of sleep and sedentary behaviour (objectively measured 
by accelerometer) at baseline, four and twelve months. 
 Uptake of the ERS by participant self-report at approximately four weeks and four 
months. 
 Adherence to the ERS using a composite measure to describe the proportion in each 
arm of the trial who achieved the primary outcome at four months and were still doing 
so at twelve months. 
 Monetary costs of intervention development including the ‘welcome pack’, with a view 
to costing the (potential) roll-out of the intervention to a wider population. 
 Self-reported monetary costs of the use of the ERS, and (for the treatment arm) the 
use of the web-based support package, at four and twelve months.  
 Mediation measures analysis (i.e. self-reported perceptions of physical activity 
confidence, importance, autonomy and relatedness, and use of self-monitoring and 
goal setting).  
 Moderation analysis, i.e. subgroup analyses for participant characteristics and ERS. 
 Incremental cost per quality-adjusted life year (QALY) at twelve months. 
 Measures of engagement with e-coachER, and its content, and use of self-monitoring 
and goal setting functions, captured on the software platform (LifeGuide).  
 Qualitative interviews with intervention arm participants focusing on their experiences 
with ERS and the additional e-coachER intervention. 
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STUDY SPONSOR AND FUNDER 
The study sponsor is University of Plymouth.  Selected sponsorship tasks will be delegated to the 
Plymouth University Peninsula Schools of Medicine and Dentistry (PUPSMD) under the terms of an 
appropriate service level agreement. 
The study was initially funded by a grant of £1,372,155.80 from the National Institute for Health 
Research (NIHR) Health Technology Assessment (HTA) Programme. This was subsequently reduced 
to £900,000 in line with a reduced sample size. The grant reference number is 13/25/20.  The grant 
will be held by the University of Plymouth.  
 
ROLES AND RESPONSIBILITIES OF TRIAL OVERSIGHT COMMITTEES 
Trial Management Group  
A Trial Management Group (TMG) including the Chief Investigator, study statistician, trial manager, 
health economist, lead for process evaluation, lead for intervention development, and other relevant 
personnel as required (e.g. data manager, patient representatives, Principal Investigators) will meet 
regularly. The TMG (and other small working groups such as outcomes group, process evaluation 
group, recruitment group, intervention development and review group, PPI group) will meet 
approximately every four weeks in person or by teleconference throughout the set-up and internal pilot 
of the study to review progress, resolve day-to-day problems and monitor participant recruitment 
ahead of progression to the full trial. Thereafter the TMG will continue to meet regularly to review and 
respond to emerging issues, as well as to monitor follow-up, oversee budgetary issues, prepare draft 
reports, discuss analysis and results, and ultimately the final report. The TMG will report to the Project 
Management Group. 
Project Management Group  
A Project Management Group (PMG) including the Chief Investigator, Principal Investigators, co-
applicants, Clinical Trials Unit (CTU) trial manager, ERS managers and PPI representative will meet 
quarterly, usually by teleconference, to provide wider multi-disciplinary input and oversight for the 
study. Interim communication/discussions will be by telephone or email, as required. 
Trial Steering Committee 
A Trial Steering Committee (TSC) including an independent chair, independent clinicians and/or 
academics with relevant expertise, independent statistician/methodologist with relevant expertise and 
a representative contributing a patient/public perspective will oversee the conduct of the trial. The TSC 
will meet in person or by teleconference before the start of the internal pilot study, before the start of 
the main trial and at least annually thereafter (shortly after a Data Monitoring Committee Meeting), to 
review study progress and protocol adherence, ensure that milestones are achieved and that general 
scientific probity is maintained.  There is the option of the TSC meeting more regularly should either 
the TSC or research study team think it is necessary. The TSC will function in accordance with agreed 
terms of reference set out in a TSC Charter. 
Data Monitoring Committee 
An independent Data Monitoring Committee (DMC) will monitor the safety and ethics of the trial by 
overseeing recruitment, primary outcome data completeness and adverse event (hospitalisation) data. 
In addition, the DMC will review data from the internal pilot study to help inform a decision about 
progression to the main trial. Operating procedures for the DMC will be agreed before the start of the 
study and incorporated into a DMC charter, updated from time to time as required. The committee will 
meet once before the start of the internal pilot trial and approximately annually thereafter, by 
teleconference or face-to-face. 
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Trial Steering Committee nominations 
Nominated Members 
Name Affiliation Expertise/role Email 
Dr Sharon Simpson (Chair) Glasgow University Senior Research Fellow (MRC/CSO Social and Public 
Health Sciences Unit) 
 
Sharon.Simpson@glasgow.ac.uk 
 
Dr Mark Kelson Cardiff University Research Fellow in Statistics, South East Wales Trials 
Unit 
KelsonMJ@cardiff.ac.uk 
 
Prof John Powell Oxford University Academic public health physician & health services 
researcher (interest in e-health) expertise 
john.powell@phc.ox.ac.uk 
 
Dr Charlie Foster Oxford University Nuffield Dept of Population Health; DH policy advisor 
on physical activity & sport  
charlie.foster@dph.ox.ac.uk 
 
Mr Chris Cavanagh 
 
Retired PPI representative chriscavanagh58@btinternet.com 
Member 
Prof Adrian Taylor (CI) University of Plymouth Professor of Health Services Research Adrian.Taylor@plymouth.ac.uk 
 
 
   
Observers 
Name Affiliation Expertise/role Email 
Dr Wendy Ingram Peninsula Clinical Trials 
Unit 
Trial Manager wendy.ingram@plymouth.ac.uk  
 
Prof Rod Taylor University of Exeter Statistician and Trialist 
 
R.Taylor@exeter.ac.uk      
 
Mrs Pam Baxter University of Plymouth Sponsor representative pam.baxter@plymouth.ac.uk 
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PARTICIPANT PATHWAY 
KEY 
White boxes: activity at all sites 
Orange boxes: activity at South West and Birmingham sites 
Green boxes: activity at Glasgow site. 
ERS: exercise referral scheme. 
EA: Exercise advisor 
RA: Research Assistant 
PenCTU: Peninsula Clinical Trials Unit. 
Referral to the ERS may occur at different points, and this is indicated by parentheses. 
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STUDY PROTOCOL 
A multi-centre, randomised, controlled trial of an augmented exercise referral scheme (ERS) using 
web-based behavioural support in individuals with metabolic, musculo-skeletal and mental health 
conditions. 
KEY WORDS 
Randomised controlled trial; exercise referral scheme, web-based behavioural support. 
1 BACKGROUND & RATIONALE 
Metabolic, musculo-skeletal and mental health conditions place a major and increasing burden on 
health care resources, workplace sickness and absenteeism, as well as on individuals.  Health 
problems associated with being overweight or obese, for example, cost the NHS more than £5 billion 
every year. There may be an increase from 2.6 million to > 4 million people with diabetes in the UK by 
2025 as a result of more routine health checks. Hypertension and diabetes significantly contribute to 
premature mortality and morbidity related to cardiovascular disease, stroke and other serious illness.  
Over one million adults each year consult their general practitioner with osteoarthritis and related 
conditions and this is expected to rise with increasing obesity. Depression is one of the most common 
reasons for consulting a general practitioner within the UK, and the associated economic burden is 
considerable and expected to worsen. Low mood and depression are common co-morbidities with 
metabolic and musculo-skeletal conditions. 
   
The role of exercise 
Across the UK the associated costs of inactivity are estimated at £1billion - £1.8billion (DH, 2011).   
Evidence-based guidelines (e.g. DH, 2011) recommend both aerobic and resistance exercise training 
for improving health markers and quality of life among those with common chronic metabolic 
conditions (i.e. obesity – NICE, 2010; hypertension – NICE, 2011; type 2 diabetes - NICE, 2008a) and 
musculo-skeletal conditions (e.g. osteoarthritis– NICE, 2008b), and mostly aerobic exercise for 
preventing and reducing depression (NICE, 2009). Significant health benefits and reduced health care 
costs could be gained with even a 10% increase in the proportion of the population, especially those 
with medical conditions, achieving the public health guidelines of at least 150 minutes of moderate to 
vigorous physical activity (MVPA) per week (DH, 2011).   
The challenge of increasing physical activity  
Patients with obesity, hypertension, type 2 diabetes, osteoarthritis and depression are less physically 
active than the general population (DH, 2011), and need greater support to overcome real and 
perceived barriers to increase physical activity (PA). Increases in PA amongst the least active have 
the potential to provide the largest impact on health but any benefits dissipate without maintained 
exercise (Dunstan, 2005). Since lower adherence, and lower exercise training volume and intensity, 
reduces health benefits, the challenge is to find appropriate ways to support sustained increases in 
aerobic and resistance exercise for those with or at risk of a medical condition.  
A variety of initiatives have been explored to promote PA within primary care, including referring 
patients to ‘exercise on prescription’, i.e. exercise referral scheme (ERS). In the UK, ERS has been 
one of the most widespread approaches to promoting PA, with an estimated 600 schemes (involving 
up to 100,000 patients per year) linked to over 90% of primary care organisations (BHF, 2010).  
Effectiveness of ERS 
Evidence from a meta-analysis of robust trials on the effectiveness and cost-effectiveness of ERS 
(Pavey et al, 2011a) indicates a small increase in the proportion of participants who achieved 90-150 
minutes of PA of at least moderate intensity per week, compared to control at 6-12 month follow-up 
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among at risk individuals. But uncertainty remains in the effects for patients with specific medical 
conditions since no study assessed long-term PA objectively.  
Factors influencing effectiveness 
In a systematic review (Pavey et al, 2012) pooled ERS uptake (attendance at the first exercise 
referral session) ranged from 66% in observational studies to 81% in randomised controlled trials, 
and adherence from 49% in observational studies to 43% in randomised controlled trials.  
Predictors of uptake and adherence have rarely been explored but Pavey and colleagues (2012) 
reported that whilst women were more likely to begin an ERS, they were less likely to adhere to it 
than men, and also older people were more likely to begin and adhere to an ERS. ERS may help 
patients become familiar with concepts such as exercise type, intensity, frequency and duration of 
exercise, matched to their medical condition, and target key processes of behaviour change. 
However, the following features of an ERS may reduce uptake and adherence (BHF, 2010): 
inconvenience, cost, limited sustainable PA support (e.g. for 10 weeks), and low appeal for 
structured exercise and/or the medical model, i.e. ‘exercise on prescription’, which does little to 
provide autonomous support nor empower patients to develop self-determined behaviour to manage 
chronic medical conditions (Rouse et al, 2011).  
Development of the trial intervention (e-coachER) 
The LifeGuide platform has been extensively used to develop and evaluate acceptability and impact of 
behaviour change and self-management interventions with a variety of clinical groups, including in 
primary care (Lloyd et al, 2013; Williams, 2013; Yardley, 2010; 2011). It provides a researcher-led tool 
to develop interventions drawn from theory and evidence of effective techniques (Greaves 2011; 
Michie et al, 2009).  
The proposed research therefore seeks to examine if web-based support using the LifeGuide platform 
(www.lifeguideonline.org/), to be referred to in this study as e-coachER, can be coherently combined 
with usual ERS to provide an effective and cost-effective approach to producing a sustained increase 
in PA. Both technologies involve relatively low cost (Anokye et al, 2011; Benaissa, 2012), and the 
proposed intervention has the potential to be rolled out across the UK.  The UK prevalence of patients 
with obesity, hypertension, type 2 diabetes, OA and risk of depression is high and patients with these 
conditions are routinely referred to ERS (BHF, 2010). Should the approach prove to be effective there 
is considerable potential for patients with other chronic medical conditions (e.g. low back pain, heart 
disease), to be referred for exercise in more specialist services with e-coachER support.    
A review of web-based public health interventions concluded that adding some human contact results 
in better long-term outcomes in mood (Newman et al, 2011). LifeGuide-based interventions combined 
with some human support have provided effective support for patients to self-manage various health 
behaviours over an extended period, including weight management, and will be used for the first time 
in this trial to support patients concurrently attending an ERS.  
E-coachER was developed between July 2014 and January 2015, predominantly by researchers at 
the University of Southampton and Plymouth, and with input from PPI for beta testing and pre-piloting 
the intervention. A Welcome Pack is initially given to participants in the intervention arm, to include a 
User Guide, pedometer and fridge magnet with recording strips for monitoring daily physical activity 
steps and minutes of moderate intensity physical activity. Contact details are provided for support from 
a facilitator to assist with IT issues if required.    
Once users have registered and logged on, e-coachER comprises seven short ‘steps to health’ which 
aim to increase uptake of the ERS support and the cognitive and behavioural skills to remain 
physically active. It is interactive in allowing users to record the amount of physical activity achieved, 
set and review weekly goals, and receive feedback. Throughout, there are short stories about how 
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others have used the support and overcome barriers. There are also links to carefully vetted websites 
(e.g. NHS, charities) on exercise and health, other local physical activity opportunities, and ways to 
use tracking software to monitor a range of health outcomes and behaviours.  
Summary 
For patients with chronic medical conditions, additional support from an exercise practitioner may be 
necessary to help them overcome initial and on-going barriers to maintaining a more physically active 
lifestyle, but it is unclear if current ERS schemes alone can provide this support. Traditional ERS may 
also create barriers for some patients but have the potential to provide valuable personal support and 
the opportunity to overcome barriers. We hypothesise that the additional support provided by e-
coachER will improve the level of access to initial ERS support, improve the level of motivational 
support, and improve adherence to the ERS over a longer period of time than usual ERS, and thereby 
result in improved levels of sustained PA. 
 
1.1 CHANGE OF PRIMARY OUTCOME MEASURE (SUBSTANTIAL AMENDMENT 04 dated 07 
SEPTEMBER 2016) 
1.1.1 Original trial design 
The original design of the trial was a multicentre, parallel group, randomised controlled trial with an 
internal pilot.  The primary outcome was the achievement of at least 150 minutes of MVPA measured 
objectively by accelerometer over one week at twelve months.  The internal pilot phase was scheduled 
to run between July 2015 and October 2015 during which time 180 patients were to be recruited to 
provide sufficient information to justify progression to a main trial.   For the main trial, a further 1220 
patients were to be recruited, making a total of 1400 participants (Figure 1).   
Progression from the internal pilot to the main trial was dependent on recruitment rate and 
engagement with the intervention according to the following scenarios:   
Criteria Scenario 3  Scenario 2 Scenario 1 
% of internal pilot sample size 
target (180 patients) recruited. 
< 65%  65 - 79%  ≥ 80%  
Intervention engagement        
(% who access e-coachER at 
least once) 
< 65%  65 - 79%  ≥ 80%  
Proposed Action No 
progression  
Discuss with TSC and funder 
about progression and resources 
needed to achieve target.  
Proceed to 
full trial. 
Qualitative interviews with eligible non-participants, and participants not initially engaging with the 
intervention were to be conducted to inform the discussion about progression and ways to improve 
recruitment and engagement.  There was no set progression target for recruiting a fixed proportion of 
patients with each of the six clinical conditions of interest since numbers were likely to be small across 
the three sites after only three months.   
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proposed) and presented to the funder. The funders invited the submission of a detailed recovery 
plan.  
 
1.1.2 Recovery Plan: Proposal 
The recovery plan comprised:  
1. Change the primary outcome measure to a continuous variable (i.e., total weekly MVPA 
minutes recorded by accelerometer in ≥10 minute bouts) at 12 month follow-up, resulting in a 
reduced sample size, from 1400 originally to 332 participants (for an ES of 0.4) or to 413 (ES 
of 0.35), allowing for 20% attrition. It was estimated that a sample size of 562 participants 
would be needed with an ES of 0.3, and this was felt to be unachievable with the available 
funding.  
2. Continue recruitment activity for a short time to confirm that recruitment according to the 
revised target, across all three sites, could be achieved.  
1.1.3 Recovery Plan: Scientific rationale and justification for reducing the sample size 
Original sample size calculation 
This sample size was based on the previous HTA systematic review of ERS (Pavey et al 2011a & 
2011b) that showed that trials up to that time had primarily reported their outcomes according to 
percentage of participants reaching the threshold of 150 minutes of MVPA per week. Using this binary 
outcome, it was estimated that recruiting 700 participants per group in the e-coachER trial would able 
us to detect a difference at 12-months follow up of at least 10% (intervention group: 53% vs. control 
group: 43%) and assuming an attrition rate of 20% and small effect of clustering (ICC: 0.006) at 90% 
power and 5% alpha. The exploratory modelling indicated a change of ≥10% is required for the 
intervention to achieve an incremental cost effectiveness ratio of <£20,000/ QALY. 
Revised sample size proposal 
The required sample size was recalculated considering the difference between groups in MVPA in 
minutes i.e. considering the primary outcome as continuous. In absence of a published minimally 
important difference for MVPA, assuming a ‘small’ to ‘moderate’ standardised effect size of 0.4, it was 
estimated that 132 participants per group at 90% power and 2-sided alpha of 5% were required (using 
‘sampsi’ in STATAv.14). Allowing for a 20% attrition rate, a total of 332 participants would need to be 
recruited. 
Following presentation of this revised sample size proposal and discussion with the funder, it was 
agreed that the trial sample size be revised and be based on a standardised effect size of 0.35 and a 
total of 413 participants recruited. Assuming an effect size of 0.35, provides 88% power at a 2-sided 
alpha of 5% assuming 20% attrition or 90% power at a 2-sided alpha of 5% assuming 16% attrition. 
Given that the e-coachER intervention is being delivered at the level of the individual participant, a 
clustering effect has not been factored into this revised sample size calculation.  Based on the 
baseline standard deviation for MVPA total weekly minutes in ≥ 10 minute bouts of 104 to 113 
reported by Harris and colleagues (Harris, 2015), an effect size of 0.35 would correspond to a 
between group difference of 36 to 39 minutes of MVPA/week.  
While international reviews and guidance have clearly identified the importance of PA for preventing 
and treating patients with the chronic conditions that we are recruiting in the e-coachER trial, it is less 
clear precisely how much change in physical activity would contribute to a minimally important clinical 
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difference (across all our target clinical groups). Public health guidelines of 150 minutes of MVPA per 
week are widely accepted but even small increases in PA and reduced sedentary time among the 
least active are likely to accrue health benefits (Bouchard et al, 2015; Warburton et al, 2016), and be 
cost-effective, especially for a low-cost web-based intervention. But detecting small differences 
(compared with a control group) usually requires very large sample sizes which are beyond the scope 
of research funding. We will be able to apply the trial data of a change in MVPA in minutes to existing 
and emerging cost-effectiveness models; a paper by Anokye is under review, and others have done 
this (e.g., Larsen, 2015).  
Following our previous systematic review of ERS and since the approval of funding of the e-coachER 
trial we continue to monitor relevant literature on the effectiveness and cost-effectiveness of ERS, and 
there have been no further systematic reviews or original studies of relevance to the ERS literature. 
However, interest in web-based interventions to promote physical activity has continued to grow. 
Several systematic reviews have been identified (e.g. Joseph et al, 2014 – 72 studies; Devi et al, 2015 
– 8 studies), and at least 15 original studies that have reported on the effects of technology-based 
interventions on PA since 2013. The reviews have included studies with a wide range of interventions 
(from quite simple self-monitoring to ones with complex multiple behaviour change components), 
targeted at different clinical groups with different baseline levels of physical activity, with various 
physical activity outcomes reported (very few using objective measures), and with mostly short-term 
follow-ups. Also, some comparisons are with no intervention and others are with human contact, 
though none report on the effects of adding web-based support to ERS. This makes their relevance to 
assessing the effectiveness and cost-effectiveness of our e-coachER intervention limited or unclear. 
But some general findings are important; the overall effect size for web-based and technology 
interventions is small to moderate (up to 0.4), but there is evidence that more rigorous studies, 
interventions with more behaviour change components, and ones targeted at less active populations 
are more effective. Given that an effect size of 0.4 would be equivalent to approximately 42-45 
minutes of MVPA per week, we searched for individual studies reporting such a between group 
difference at follow-up to identify the study characteristics and similarities to e-coachER. We also 
noted the sample size justification for each study that included minutes of MVPA as a continuous 
outcome.  
Of 10 individual studies (involving likely comparable participants to those in e-coachER) reporting 
outcomes from a comparison of web-based intervention versus control, since 2013, 4 reported 
accelerometer assessed physical activity. Including 2 further studies with a published protocol, the 
estimated sample sizes required to detect significant between group differences in continuous physical 
activity outcomes was 48 to 397.  
In a study with a total of 94 participants with angina, Devi et al (2014) reported at 6 months the 
following effect sizes in favour of a web-based intervention, compared with usual care, for daily steps 
(effect size =0.24, 95% CI:–358 to 2324, P=0.15), daily energy expenditure (0.38, 95% CI: –35.17 to 
250.47, P=0.14), duration of sedentary activity (0.55, 95% CI: 0.190 to -0.205, P=0.20), duration of 
moderate activity (0.55, 95% CI: 0.244 to -0.261, P=0.24), recorded by accelerometer.  
In a study with a total of 300 participants, Harris et al (2015) reported at 12 months a between group 
difference in favour of the digital intervention (pedometer monitoring and reflection, in primary care) of 
609 steps/day (95% CI: 104 to 1,115, p = 0.018) and 40 minutes/week MVPA (95% CI: 17 to 63, p = 
0.001).  
In a study with a total of 179 participants at 3 months follow-up, Compernolle et al (2015) reported a 
net difference in daily step counts (recorded by a user-blinded pedometer) of 895, and 12% difference 
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in the proportion achieving the recommended 10,000 steps per day, in favour of the intervention 
compared with a control. This study included both pedometer and web-based support like e-coachER.  
Finally, the only study (Wijsman et al, 2013) we have found which used the same GeneActive 
accelerometer used in e-coachER reported that a web-based intervention, offered to half the 226 
participants, led to a mean increase of 11.1 minutes per day spent in MVPA, compared to a mean 
decrease of 0.1 minutes in the control group (P =0.001) at 3 months.  
Systematic reviews (e.g. Davies et al, 2012) have also highlighted the importance of maximising 
sustained engagement in web-based interventions for enhancing change in the target behaviour. 
Recent studies (e.g. Morrison et al, 2014) confirmed that self-assessment and tailored feedback were 
important to increase engagement, and periodic communications help to maintain participant 
engagement. The e-coachER trial links closely to another LifeGuide delivered intervention (for weight 
loss) called POWeR, in which a combination of face to face and web-based support led to the greatest 
weight loss (Yardley et al, 2014); those completing at least 9 of the 12 recommended brief sessions 
lost 6.7kg, whereas those who did not, lost 1.5kg at 12 months. Our intervention also provides ERS 
practitioner support in addition to e-coachER web-support. We also seek to maximise engagement 
with e-coachER support, with follow-up automated e-mails for 12 months. Based on the first 60 
participants allocated to the e-coachER intervention over 65% have accessed the on-line support 
system, and we continue to monitor that through our process evaluation.   
1.1.4 Recovery Plan: Outcome 
The funder accepted the recovery plan, stipulating the following conditions: 
1. Change the primary outcome measure to a continuous variable, as proposed.  
2. Continue recruitment and achieve a sample size of 413 by the end of March 2017 (i.e. a 5 
month extension to recruitment). 
1.1.5 Summary 
 The primary outcome has been changed to a continuous variable, i.e. total weekly minutes of 
MVPA in ≥10 minute bouts, recorded objectively by accelerometer, over one week at twelve 
months.   
 As a result of changing the primary outcome from a dichotomous to a continuous variable, the 
sample size has been reduced from a total of 1400 participants to 413 participants (206 per 
group) based on detecting a between group effect size of 0.35, allowing for 20% attrition, with 
5% significance and 88% power. 
 The recruitment window will be increased from 15 to 20 months.  
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2 OBJECTIVES AND OUTCOME MEASURES 
To determine whether the addition of a web-based support package to usual ERS increases the 
minutes of moderate to vigorous intensity physical activity (MVPA) at twelve months, compared with 
ERS alone, and whether such an intervention is cost-effective. 
2.1 Objectives 
The objectives are as follows: 
 To determine whether in the intervention participants compared to the controls, there is an 
increase in the total weekly minutes of MVPA at twelve months post-randomisation. 
 To determine whether in the intervention participants compared to controls there is an increase in 
the proportion of participants who:  
  
o Take up the opportunity to attend an initial consultation with an exercise practitioner 
o Maintain objectively assessed physical activity at four and twelve months post-randomisation 
o Maintain self-reported physical activity at four and twelve months post-randomisation 
o Have improved health-related quality of life at four and twelve months post-randomisation 
 
 To quantify the additional costs of delivering the intervention and determine the differences in 
health utilisation and costs between the intervention and control arms at twelve months post-
randomisation.  
 To assess the cost-effectiveness of the intervention compared with control at twelve months post 
randomisation (incremental cost per QALY) and over the lifetime perspective (incremental cost per 
QALY) using a previously developed decision model to estimate future costs and benefits.  
 To quantitatively and qualitatively explore whether the impact of the intervention is moderated by 
medical condition, age, gender and socioeconomic status, or ERS characteristics, IT literacy. 
 To quantitatively and qualitatively explore the mechanisms through which the intervention may 
impact on the outcomes, through rigorous process evaluation and mediation analyses.  
All primary and secondary outcomes will be collected on both intervention and control arm participants 
unless otherwise indicated below. 
2.2 Primary outcome 
The primary outcome is the achievement of more weekly minutes of MVPA, in ≥10 minute bouts, 
recorded objectively by accelerometer, over one week at twelve months compared with the control 
group. 
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2.3 Secondary outcomes 
Secondary outcomes are:  
 Total weekly minutes of MVPA in ≥10 minute bouts, recorded objectively by accelerometer, over 
one week at four months. 
 Achievement of at least 150 minutes of MVPA, measured objectively by accelerometer, over one 
week at four and twelve months post-randomisation. 
 Self-reported achievement of at least 150 minutes of MVPA over one week using the Seven Day 
Physical Activity Recall Questionnaire at four and twelve months post randomisation. 
 Self-reported weekly minutes of MVPA at four and 12 months.  
 Self-reported health-related quality of life, assessed by the EQ-5D-5L and SF12v2 at four and 
twelve months post randomisation. 
 Self-reported symptoms of anxiety and depression, assessed by the Hospital Anxiety and 
Depression Scale (HADS) at four and twelve months post randomisation. 
 Average daily hours/minutes of sleep and sedentary behaviour (objectively measured by 
accelerometer) over one week at four and twelve months post randomisation. 
 Uptake of the ERS by participant self-report at approximately four weeks and four months post 
randomisation. 
 Adherence to the ERS, using a composite measure to describe the proportion in each arm of the 
trial that achieved the primary outcome at four months and were still doing so at twelve months. 
 Process measures, to be described and included in mediation analysis including 1-4 self-reported 
survey items for each of the following: self-efficacy/confidence to be physically active; importance 
of being physically active; relatedness (perceived frequency and availability of support); perceived 
autonomy/control over physically active choices; involvement in self-monitoring and planning PA.  
 In the intervention group, measures of engagement with e-coachER, and its content, and use of 
self-monitoring and goal-setting functions, captured by the software platform (LifeGuide).  
 Qualitative interviews with participants in the intervention arm, focusing on their experiences with 
ERS and the intervention. Also, interviews with eligible participants who decline to enter the study 
to assess acceptability of trial methods.  
2.3.1 Economic outcomes 
The costs associated with the following will be determined:  
 Development of the intervention to include the ‘Welcome Pack’, with a view to costing the 
(potential) roll-out of the intervention to a wider population. 
 Self-reported monetary costs of health service use, use of the ERS and use of the web-based 
support package, at four and twelve months.  
 Costs of support (including training) provided by the e-coachER facilitator (RA) and LifeGuide 
technician.  
 Health and personal social care use (self-reported at four and twelve months). 
 Personal costs for participation in PA (including use of ERS) at four and twelve months. 
The main outcome of the economic analysis will be the incremental cost per Quality-Adjusted Life-
Year (QALY) at twelve months, based on EQ-5D-5L.  
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3 TRIAL DESIGN 
The design is a multicentre, parallel group, randomised controlled trial. Patients will be individually 
randomised to receive usual ERS alone (control) or usual ERS plus access to a web-based support 
package (e-coachER), and motivational and technical support (intervention).  The trial will have 
parallel economic and process evaluations. 
In the set-up phase the research team, and ERS associates will adapt and test e-coachER. The 
Welcome Pack and platform will be tested with ERS patients and final adaptations made in response 
to users’ feedback.  
Thereafter, 413 patients will be recruited to determine the effectiveness and cost-effectiveness of the 
addition of the intervention to ERS, relative to usual ERS alone.   
4 STUDY SETTING 
The study is a multicentre study with three participating sites – South West (Devon and Cornwall), 
Birmingham, and Glasgow, where exercise referral schemes currently exist. All participants will be 
referred by a GP or health professional working in primary care to a local exercise referral scheme in 
the community. Those participants randomised to receive the intervention will be given access to the 
e-coachER support package.   
5 ELIGIBILITY CRITERIA 
5.1 Inclusion criteria 
Patients must satisfy the following criteria to be enrolled on the study: 
 Aged 16-74 years 
 Have one or more of the following: 
o Obesity (BMI30-40) 
o Diagnosis of hypertension 
o Type 2 diabetes 
o Prediabetes (‘borderline diabetes’) 
o Lower limb osteoarthritis 
o Recent history of treatment for depression (i.e. last two years) but may not be currently 
receiving treatment  
 Categorised as ‘Moderately Inactive’ or ‘Inactive’ according to the physical activity index 
calculated from the GP Physical Activity Questionnaire.  
 Be contactable by e-mail and have at least some experience of using the internet.  
5.2 Exclusion criteria 
Patients who meet any of the following criteria will be excluded from study participation: 
 Unstable, severe and enduring mental health problem that may limit involvement in the trial. 
 Being treated for an alcohol problem or drug addiction that may limit involvement in the trial. 
 Inability to use written materials in English, unless they have access to a readily available 
designated friend or family member to translate. 
 Does not meet the inclusion criteia for a referral to the ERS, e.g. has a medical condition that 
is contra-indicated for the ERS.  
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6 RECRUITMENT  
Eligible participants will be patients with the chronic conditions of diabetes, prediabetes, obesity, 
hypertension, osteoarthritis or a history of depression who are suitable for referral to a local exercise 
referral scheme from a health professional working in primary care. 
6.1 Patient identification and approach  
Patients will be recruited in more than one way since the usual care pathway varies between sites and 
participating GP practices. At participating GP practices, patients being actively referred to an ERS or 
opportunistically found to be eligible for an ERS (e.g. during a routine NHS health check or visit to a 
surgery) may be identified by the GP/ practice research nurse / PCRN research associate / other 
health professional as being potentially eligible for the study.  In addition, the GP database will be 
searched by practice staff or PCRN research associate, for patients who are potentially eligible for an 
ERS, and such patients invited for an appointment with the GP / practice research nurse / PCRN 
research associate/ Research Assistant to establish eligibility for ERS.  Referral to the ERS will be 
made by a member of the primary care team. 
At some sites, potential participants will also be identified by exercise advisors from patients referred 
by the GP for assessment of suitability for the ERS. 
6.2 Approach/invitation to participate 
Depending on the identification route and local care pathway, a member of the GP practice team or 
the exercise advisor will provide potential participants with a trial Information Pack (by post or by 
hand). Alternatively, potential participants may be given a summary study information sheet containing 
contact details for the local RA who will send an Information Pack directly to the patient once contact 
has been made by the patient. 
The Information Pack comprises an outer envelope displaying brief information about the trial 
containing an invitation letter, Participant Information Sheet and reply slip.  Patients will be asked to 
indicate on the reply slip if they are interested in participating in the trial, and to return the reply slip to 
the local RA in the Freepost envelope provided. Patients may also contact the relevant site research 
team via a dedicated answer phone at each site or by e-mail.  
In addition, interested patients will be asked by the exercise advisor if they are willing for their 
contact details to be passed on by the ERS service to the local RA, and if so, the local RA will make 
contact with the patient as described in Section 6.3. 
6.3 Screening and consent 
On receipt of a completed reply slip (or equivalent expression of interest), a member of the local 
research team will contact the potential participant to outline the study, answer any queries and 
establish eligibility for the trial.   
If the patient is interested in taking part in the trial and appears eligible, the research team member 
will offer to arrange a face-to face meeting with the patient to complete the consent process, provide 
the wrist-worn GENEActiv accelerometer and baseline questionnaire. Alternatively, the consent 
process can be completed during this same telephone call and the researcher can post the 
accelerometer and baseline questionnaire to the patient.    
6.3.1 Face to face consent process 
The face-to-face screening/consent appointment will usually take place at the location of a primary 
healthcare provider (which will usually be the GP practice), or at the location of the ERS provider 
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(which is usually a leisure centre).  Other locations may also be used to maximise convenience for 
participants and availability of quiet and secure office space, such as in pharmacies, and academic 
centres and at peoples’ homes.  
At this session, the research team member will describe the study, answer any questions the patient 
may have and check final eligibility for the ERS and trial, including the General Practice Physical 
Activity Questionnaire (GPPAQ). Patients who are willing and eligible to take part will be asked to 
complete, sign and date the study consent form, which will also be signed and dated by the person 
obtaining consent.  A copy of the signed consent form will be given to the participant and the original 
signed form will be retained in the Investigator Site File. 
6.3.2 Telephone consent process 
If the patient is unable or unwilling to meet with the researcher in person, consent can be obtained via 
the telephone. Patients will be provided with the same information as in the face to face process 
(above) and given the opportunity to have any questions answered. Inclusion/exclusion criteria, 
including the GPPAQ, will be checked. If patients are willing and eligible to take part, the researcher 
will read out the separate elements of the consent form and get the patient’s verbal assent for each 
one. The researcher should initial each box on the consent form to indicate that each clause has been 
read to and agreed by the patient. The researcher should sign and date the consent form. A copy of 
the researcher-only signed consent form will be sent to the participant and the original researcher-only 
signed form will be retained in the Investigator Site File. Given the nature of the study, there is no 
requirement for participants to sign the consent form themselves in the case of telephone consent. 
6.4 Planned recruitment rate 
The recruitment target is 413 participants (138 participants per site).  The following strategies to 
maximise recruitment will be used as necessary: 
 Encourage practices to maintain or increase routine identification and referral of patients into 
local ERS’s. 
 Engage with GP practices and/or exercise advisors at the ERS’s to identify eligible patients.   
 Raise patient awareness of the study at GP practices and ERS’s  (e.g. presentations, posters, 
website) to foster opportunistic interest. 
 Site PI’s and RAs to work closely with the local Research Network, to identify practices for 
recruitment in a timely manner. 
 Utilise the site research assistant (RA) to maintain a proactive approach to recruitment and 
monitor ERS waiting times (referral throughput) to ensure the recruitment rate approximately 
matches the ERS capacity. 
6.4.1 Addressing trial and intervention ‘reach’ 
There is a risk of recruiting a higher proportion of patients who tend to be more physically active (and 
hence with less to gain from the intervention), and only those familiar with web-based and mobile 
technologies. In order to recruit less active patients and those with only limited familiarity with 
internet and mobile technologies the following approaches have been and will continue to be used:  
 Conduct focus groups and individual interviews with patients and practitioners with relevant 
experience to determine how best to describe the study and intervention in recruitment and 
intervention (e.g. Welcome Pack) materials.  
 Work with local authority and third sector organisations to identify local opportunities to ensure 
that appropriate IT support can be described in trial materials and provided to participants 
receiving e-coachER.  
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 Identify specific roles for the e-coachER RA to support patients’ use of the technology.  
 Continue to monitor local and academic reports on optimising the use of e-coachER for those 
with low IT use (e.g. older people, disadvantaged populations).  
7 BASELINE DATA COLLECTION  
 
Baseline data collection includes demographic data, a simple IT literacy question the baseline 
questionnaire booklet and baseline accelerometry data. Demographic data will be collected by direct 
questioning at the time of consent and recorded in the case report form (CRF). 
Participants attending a face to face screening/consent visit will complete the baseline questionnaire 
booklet at this visit, following consent. Each participant will also be provided with a GENEActiv 
accelerometer. The researcher conducting the face-to-face screening appointment will attach the 
accelerometer to the participant’s non-dominant wrist. The participant will be asked to wear the 
accelerometer for the next seven days and to return it to the Peninsula CTU after that time, in the pre-
paid envelope supplied. The researcher will send the complete baseline questionnaire booklet to the 
CTU. 
For participants consenting to the study by telephone, the local researcher will post a copy of the 
researcher-signed consent form, baseline questionnaire booklet, accelerometer, instructions for use 
and a pre-paid return envelope to the participant following verbal consent. The completed 
questionnaire booklet and used accelerometer will be returned directly to the CTU by the participant.  
The CTU will send a standard letter to participants three days after the accelerometer has been 
administered by post, as a prompt to the participant to begin wearing the accelerometer, if not already 
doing so.    
The CTU will send up to two reminder letters (at 2 and 4 weeks) and/or make two telephone calls) to 
participants to prompt the return of both accelerometers and baseline questionnaire booklets.  If the 
participant has not returned the accelerometer after 6 weeks the local Research Assistant will remind 
the participant via the telephone. Participants who return the accelerometer to the CTU will receive a 
high street/online store voucher of £20 as a ‘thank you’ payment. 
8 RANDOMISATION  
Following receipt of the baseline survey and accelerometer, randomisation will be carried out by the 
PenCTU. Randomisation will be conducted by means of a secure, password protected web-based 
system created and managed by the CTU in conjunction with the trial statistician. Participants will be 
randomised to usual ERS or usual ERS plus access to e-coachER in a 1:1 ratio, stratified by site 
(1=SW; 2=Birmingham; 3=Glasgow) with minimisation by patient's perception of main medical referral 
reason (1=control diabetes; 2=weight loss; 3=lower blood pressure; 4=manage lower limb 
osteoarthritis symptoms; 5=manage mood/depression), IT literacy level (1=lower confidence; 2=higher 
confidence). To maintain concealment, the minimisation algorithm will retain a stochastic element.  
 
CTU will inform the participant of the treatment allocation by standard letter. Participants allocated to 
the intervention arm will also be sent an e-coachER Welcome Pack (see section 7). 
Blinding of trial participants is not possible, given the nature of the intervention. Given that the primary 
outcome is an objective measure of physical activity recorded by the wrist-worn accelerometer and the 
secondary outcomes will be assessed by participant questionnaire self-completion, the risk of 
assessor bias is likely to be negligible in this study. However, to minimise any potential bias, the 
statistical analysis will be kept blinded and the code for group allocation not broken until the primary 
and secondary analyses have been completed.  
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9 TRIAL INTERVENTION 
The e-coachER intervention is an engaging support package to help people on an ERS to become 
and remain more physically active. The intervention consists of an interactive website plus a 
pedometer and a fridge magnet with paper strips for recording the number of daily activity steps and 
minutes of moderate intensity physical activity. Without engagement, the intervention can have no 
additional benefit. The first point of contact with the intervention is therefore a user-friendly Welcome 
Pack. Figure 2 shows the version to be given out at face-to-face opportunities; a non-boxed version 
will be used for mailing to participants.   
 
The Welcome Pack contains a User Guide with a unique User ID to enable participants to register and 
log into the e-coachER website easily. It also includes a good quality pedometer and the fridge 
magnet with attached record sheets. Contact details for further IT support are also provided. The User 
Guide shows screenshots of pages in the e-coachER website, including the seven ‘Steps to Health’.  
 
Figure 2: The Welcome Pack 
   
 
E-coachER aims to increase uptake of support offered by exercise practitioners at the ERS, but also 
provides a stand-alone interactive website to facilitate skill development to remain physically active.  
 
The support provided by the e-coachER website is autonomous in that participants set their own 
(hopefully progressive) targets and choose their preferred types of activities.  Appendix 1 shows each 
element of the e-coachER support package, the objective of each element, the behaviour change 
technique used to achieve each objective, and the strategy for implementing each behaviour change 
technique. The Research Assistant at each site will provide general and local motivational IT support 
and the LifeGuide technician will support minor operational issues across all sites.  
 
10 TRIAL ACTIVITIES AND FOLLOW-UP  
The study schedule is given in Table 1.  
 
10.1 Exercise Referral Scheme 
Participants will attend the ERS according to local standard care, typically after completion of baseline 
assessments and randomisation to trial arm. Protocols for ERS’s have been agreed at each site. These 
vary from the more traditional approach with patients receiving supervised exercise sessions by a 
qualified exercise practitioner 1-2 times per week to more office-based support and signposting to 
exercise in a variety of community settings.  
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10.2 Follow-up assessments 
At four weeks post-randomisation, the CTU will email all participants a survey about ERS attendance. 
At four and twelve months post-randomisation, the CTU will post all participants an explanatory cover 
letter, an accelerometer (with an instruction sheet), self-completion questionnaire booklet, and a pre-
paid envelope for return of the accelerometer and questionnaire booklet.   
The CTU will send a standard letter to participants approximately 1 week prior to the 4 month and 12 
month follow-up assessments, as notification that the items listed above will shortly be sent.  
Furthermore, the CTU will send a standard letter to participants three days after the accelerometer has 
been administered, as a prompt to the participant to begin wearing the accelerometer, if not already 
doing so.    
The CTU will send up to two reminder letters to participants (supported by a telephone call or email as 
required) to prompt the return of both the accelerometer and questionnaire booklet. Participants who 
return the accelerometer to the CTU will receive a high street/online store voucher (£20 at four months 
and £20 at twelve months) as a ‘thank you’ for participating. 
 
Table 1: Study schedule 
 
Measure Baseline  4 
weeks 
4 
months 
12 
months  
(IT needs assessment at screening)     
Demographics X    
Medical condition for referral   X    
Accelerometer (worn for 1 week) - minutes of MVPA, 
sleep, and light activity per week 
X  X  X 
Sessions held with exercise practitioner (retrospective 
self-report) as an indicator of ERS engagement 
  X X 
Self-reported physical activity (7 day PA questionnaire)  X  X X 
Health & social care resource use X  X X 
EQ-5D-5L, SF12v2  X  X X 
HADS X  X X 
Process outcomes e.g. confidence, importance (1) X  X X 
Qualitative interview (sample of participants)  X X X 
Retrospective check of ERS attendance (by e-mail, 
questionnaire, and ERS attendance records) 
 X X X 
(1) See full list in section 2.3: Secondary outcomes.  
 
10.3 Retrospective check of ERS attendance by study team 
To ascertain the uptake of and adherence to ERSs, the study team shall collate information on 
participants’ ERS attendance directly from the local ERS provider.     
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10.4 Qualitative assessments  
Qualitative interviews will be conducted by a single e-coachER research assistant, as part of the 
process evaluation, based in Exeter. The main consent form for the study includes a statement that 
participants may be contacted for interview but that this part of the study is optional and participants 
do not have to agree to be interviewed. Upon contacting the participant by phone, the RA will explain 
the broad interview content, that the interview will be recorded, and processes to ensure the data 
remains confidential and anonymous during data analysis. Further verbal consent will be obtained, 
and a consent formed signed by the RA.  Interviews will be conducted either face-to-face or over the 
telephone.  All interviews will be transcribed with any personal data or ways of identifying participants 
being removed. Transcriptions will be coded, thematic analysis performed to identify key findings. The 
focus of the interviews will be linked to the phase of the research.  
10.4.1 Feasibility and acceptability of the intervention and trial methods 
 (1) To inform our understanding of recruitment feasibility and acceptability, participants who are 
eligible but who decline to join the study will be asked to indicate by return of the reply slip if they are 
willing to be contacted to determine what influenced their decision not to join the study. Questions will 
broadly focus on the following: (a) understanding of what the study/intervention is about based on the 
Information Pack materials; (b) confidence (or lack of) in using the internet; (c) perceptions of available 
support to overcome IT issues; (d) beliefs about the value of a website in the context of ERS. We will 
seek to interview as many participants as possible at this stage.  
(2) To inform our understanding of perceptions about engaging with the intervention, we will 
interview those who, within three weeks of being allocated to the on-line intervention group, (a) do not 
register on-line for e-coachER or (b) register but then never log in again; or (c) register and log in 
once, but don’t get beyond Step 1 and/or 2 (i.e. do not get involved in any of the core behaviour 
change techniques, including self-monitoring and goal setting).  Questions will broadly focus on 
perceptions of the Welcome Pack, the process of registering on-line and accessing e-coachER, and 
the initial content and support provided. We will seek to interview as many participants as possible at 
this stage.  
10.4.2 Functionality and utility to support behaviour change 
Participants from the following groups will be interviewed (a) used e-coachER a few times then 
stopped, or never get beyond say Step 3 or 4; (b) got through all seven steps. We will select a random 
sample of about 40 participants but the precise number of interviews will be determined by data 
saturation and resources available.  
The interview schedule will include questions about the value of the Welcome Pack and contents in 
helping to access e-coachER, the overall web-based support and each of the Steps to Health, in terms 
of functionality and utility to support behaviour change. Participants will be asked to identify if and how 
they thought e-coachER provided support in accessing an exercise practitioner within the ERS, and 
maintaining physical activity. Ideas for additions or revisions to e-coachER will be requested.  
Questions about support for behaviour change will also attempt to provide qualitative information 
about some of the processes within our logic model and to be assessed quantitatively within the four 
and twelve month assessments. For example, questions will focus on changes in perceived 
importance of physical activity, support used and received to increase physical activity, perceived 
changes in competence, and autonomy of decisions concerning physical activity.  
10.4.3 Interviews with e-coachER facilitators 
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E-coachER facilitators at each site will record the type and amount of support requested at an 
individual level, and provided in field notes.  Interviews with e-coachER facilitators during and at the 
end of the trial will be conducted to identify strengths and weaknesses of their supporting role.  
 
 
10.5 Withdrawal criteria  
A participant may, at any time, withdraw from the study without giving a reason and without it affecting 
his/her clinical care. Participants will be asked to give a reason for withdrawal from the study but do 
not have to provide one. Participants who wish to withdraw will be given the option to continue with 
partial follow-up, e.g. provide primary outcome data only, to minimise data loss. Participants who 
withdraw from the study will not be replaced. The CTU data management team will ensure that 
participants who formally withdraw from the study are not contacted for any subsequent follow-up data 
collection (aside from any partial follow-up arrangements made with individual participants). Data 
collected prior to withdrawal will be included in the study analysis unless a participant specifically 
requests that their data are removed from the database.   
10.6 End of trial  
Participants will normally complete the study after returning the completed twelve month questionnaire 
booklet and used accelerometer. The trial itself will end on the date that the last participant completes 
the twelve month follow-up assessments.  
11 SAFETY REPORTING 
 
11.1 Definitions 
Adverse event (AE) 
Any untoward medical occurrence, unintended disease or injury or any untoward clinical signs in study 
participants whether or not related to any research procedures or to the intervention. 
Serious Adverse Event (SAE) 
A serious adverse event in the context of this study is any untoward medical occurrence that: 
 Results in death 
 Is immediately life-threatening 
 Requires inpatient hospitalisation  
 Results in persistent or significant disability/incapacity 
11.2 Reporting requirements for this study 
The recording and reporting of non-serious AEs in this study is not required. Information about SAEs may 
be captured in a variety of ways (see below). SAE report forms will be returned to the CTU and entered 
into the study database. The CTU will prepare quarterly summaries of SAEs, listed by organ system 
where possible, for review by the DMC and Sponsor. 
11.2.2 In-patient data from questionnaires at 4 and 12 months 
The resource use questions in the self-completion study questionnaire booklets ask participants to record 
the number of in-patient episodes within a set recall period. At the four and twelve month time points, 
participants are asked to record if they have been hospitalised, the reason for any hospital admission 
during the past four and eight months respectively and whether they think that the hospitalisation was 
related to participation in this study. On receipt of a questionnaire indicating a past hospital admission, the 
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CTU will liaise with the relevant local RA who will be responsible for ascertaining further details about the 
SAE from the participant and/or GP records as appropriate.  
11.2.3 Notification of SAEs via GP  
Once a patient is recruited to the study, the participant’s GP will be notified by letter. The notification letter 
includes a request for the GP to contact the CTU in the event of the GP becoming aware of any SAE. On 
being informed of an SAE, the CTU will liaise with the relevant local RA who will be responsible for 
ascertaining further details about the SAE from the participant and/or GP records as appropriate. 
 
11.2.4 Notification of SAEs from other sources 
It is possible that the local research team or CTU may become aware of an SAE via patient or relative 
self-report or some other channel. In such cases, the local RA will be informed of the SAE in order to 
ascertain further details for reporting to the CTU. 
12 STATISTICS AND DATA ANALYSIS 
12.1 Sample size calculation 
In absence of a published minimally important difference for MVPA, assuming a ‘small’ to ‘moderate’ 
standardised effect size of 0.35, it is estimated that 413 participants total is required at 88% power and 
a 2-sided alpha of 5% assuming 20% attrition or 90% power at a 2-sided alpha of 5% allowing for 16% 
attrition. Given that the e-coachER intervention is being delivered at the level of the individual 
participant, clustering has not been factored into this revised sample size calculation.   
 
 
12.2 Statistical analysis 
All analyses will be carried out using a detailed a priori statistical analysis plan that will be completed 
and agreed with the TMG and DMC prior to closure of the trial database and the commencement of 
any data analysis.  
Analyses will be reported in full and in accord with CONSORT reporting guidelines (Schultz et al, 
2010). Recruitment, intervention and control uptake, outcome completion rates and drop out will be 
reported (with 95% CIs) as a flow diagram and we will describe baseline participant characteristics in 
the two trial arms. 
The primary analysis will compare the primary and secondary outcomes between intervention and 
control arms groups according to the principle of intention to treat (i.e. according to original 
randomised allocation) at twelve months adjusting for baseline outcome values and stratification and 
minimisation variables (recruitment site, postcode, age gender, and disease indication using logistic 
regression.  
Secondary analyses will be undertaken to compare groups at follow up across all follow up points 
(i.e. four and twelve months) using a repeated measures approach. In addition, we will seek to 
undertake secondary per protocol analyses to examine the impact of different levels of the 
adherence to the e-coachER intervention. Pre-defined definitions of per-protocol will be agreed by 
the TMG and included in the statistical analysis plan. 
The primary analysis model will be extended to fit interaction terms to explore possible subgroup 
differences in intervention effect in stratification and minimisation variables and the pre-defined 
baseline characteristics. As not formally powered, these subgroup analyses will be regarded as 
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exploratory and hypothesis-generating.  Sensitivity analysis, making different assumptions about the 
imputation model used will be conducted for both primary and secondary analyses to assess the 
likely impact of missing data.  
Contemporary mediational analysis methods (Emsley et al, 2010) will be used to explore the impact 
of process outcomes identified in the planned intervention components, including e-coachER 
engagement, use of behaviour change techniques, and motivation and processes of change (e. g., 
self-efficacy, autonomy, relatedness).  
No interim analysis of primary or secondary outcomes is planned.   
Models will be fitted using mixed effects regression models and undertaken in STATA v12.  
 
12.3 Interim analysis  
Once the recruitment period has finished, descriptive blinded analysis will be undertaken on the 
baseline data.  
12.4 Economic evaluation 
The economic analysis will include NHS, personal social services and patient perspective (NICE, 
2012), with two approaches:  
12.4.1 Within-trial-based analysis 
Resource use data will be used to determine an incremental cost per Quality-Adjusted Life-Year 
(QALY: based on EQ-5D-5L). Resource use data will be collected via follow-up surveys at four and 
twelve months, and by e-mail to capture ERS uptake and engagement. Unit costs will be taken from 
the NHS reference costs (e.g. DH, 2012), standard unit costs (e.g. PSSRU, 2011), and published 
literature. QALYs will be estimated over the trial period for individual patients using an ‘area under the 
curve’ approach. It will also be possible to present the results in the form of a cost-consequence 
analysis (disaggregated costs next to the important outcomes). Descriptive analyses will show mean 
total costs and mean utilities by trial arm and differences between trial arms. Non-parametric 
bootstrapping will be used to estimate differences in mean costs, with 95% confidence intervals, and 
incremental cost-effectiveness ratios. Uncertainty will be represented in cost-effectiveness 
acceptability curves (CEACs) and incremental net benefits for the intervention arm versus control.  
 
12.4.2 Beyond trial modelling 
A decision analytical model will be used to examine the impact of PA on lifetime risk of developing a 
series of conditions which are known to be associated with physical activity and for which more robust 
quantifiable evidence is available (CHD, stroke and type II diabetes, potentially depression- with DH 
work- EMPHASIS model underway) following extensive previous work (Anokye et al, 2011, Anokye et 
al, 2014). Costs and QALYs will be discounted at the NICE recommended rates of 1.5% p.a. The 
modelling approach will be informed by new developments in the field, particularly the EMPHASIS 
model, which is being developed at Brunel (involves Anoyke) and expected to be completed in 2017. 
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13 DATA HANDLING 
13.1 Subject numbering 
Each participant will be allocated a unique study number following receipt of the reply slip (or 
telephone call or email equivalent) indicating interest in the study, and completion of baseline 
assessments (including accelerometer), and will be identified in all study-related documentation by 
their study number and initials. A record of names, addresses, telephone numbers and email 
addresses linked to participants’ study numbers will be stored securely on the study database for 
administrative purposes.  
13.2   Data collection  
Data will be recorded on study specific data collection forms (CRFs), usually by the Research 
Assistant. Participants will complete participant-reported outcome measures. Data will be collected on 
paper for both study arms, with additional data collected from the e-coachER intervention (via the 
LifeGuide software platform) for intervention participants. An e-mail will be sent to participants at 4 
weeks with a request for information on the number of sessions held with an exercise professional as 
part of the ERS, will request a response to indicate ERS uptake. All persons authorised to collect and 
record study data at each site will be listed on the study site delegation logs, signed by the relevant PI.  
 
13.3 Data handling and record keeping 
Completed CRFs will be checked and signed at the research sites by the research assistant or 
another member of the research team before being sent to the Pen CTU. Original CRF pages and 
questionnaires will be posted to the CTU at agreed timepoints with copies of the CRF retained at the 
relevant study site. Forms will be tracked using a web-based study management system. All data will 
be double-entered by the CTU on to a password-protected database. Double-entered data will be 
compared for discrepancies using a stored procedure and discrepant data will be verified using the 
original paper data sheets. Incomplete, incoherent, unreadable or other problem data in the CRF 
pages will be queried by the CTU with study site staff during data entry to ensure a complete and valid 
dataset. Questionnaire data will not be queried with participants. The CTU may complete further 
validation of data items, perform logical data checks and raise further data queries after data collection 
has been completed. The final export of anonymous data will be transferred to statisticians for analysis 
after all data cleaning duties have been performed by the CTU, this will usually be via email or a 
removable storage device. Identifiable information will not be exported from the study database as part 
of the final export.  
Accelerometers will be received by the PenCTU and data will be downloaded via GENEActiv software, 
and linked to participant ID numbers. Files will be checked before the accelerometers are recirculated. 
Files will be then further analysed with bespoke software to classify data into levels of physical activity 
intensity using accepted cut-points. Standard operating procedures will be applied to make adecision 
about dealing with missing data. Selected primary and secondary accelerometer derived outcomes will 
be merged into an individual participant data set, and securely stored as below. 
13.4 Data confidentiality and security 
The research team will ensure that participants’ anonymity is maintained on all documents. Data will 
be collected and stored in accordance with the Data Protection Act 1998/General Data Protection 
Regulation 2018.  
Electronic study records will be stored in a SQL server database, stored on a restricted access, secure 
server maintained by Plymouth University. Data will be entered into the database via a bespoke web-
based data entry system encrypted using SSL. Access to electronic data will be permission based, 
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with access to identifiable information limited to those processing questionnaires and performing initial 
screening activities. Data entered onto the database will be backed up according to PenCTU SOPs.  
Within the CTU, anonymised paper-based study data will be stored in locked filing cabinets within a 
locked office. Any paper-based participant related identifiable data will be stored separately from the 
study data. Copies of study data retained at study sites will be securely stored for the duration of the 
study prior to archiving. 
13.5 Access to data 
The CTU data team will have access to the full dataset, including identifiable data. Site based 
researchers will have access to the dataset for participants from their site, including identifiable 
information, to perform screening activities. Other members of the study team and the CTU will have 
restricted access to anonymised study data. Access will be granted to the Sponsor and host institution 
on request, to permit study-related monitoring, audits and inspections. Access to the database will be 
overseen by the CTU data manager and trial manager.   
13.6 Archiving 
Following completion of data analysis and submission of the end of study report, the Sponsor will be 
responsible for archiving the study data and essential documentation in a secure location for a period 
of five years after the end of the trial. No trial-related records should be destroyed unless or until the 
Sponsor gives authorisation to do so.  
14 MONITORING, AUDIT & INSPECTION 
A trial monitoring plan will be developed and agreed by the TMG based on a risk assessment. This will 
involve central data monitoring but may also include on-site monitoring by the CTU trial manager. The 
Principal Investigators will be required to permit the CTU trial manager or deputy to undertake such 
monitoring as required to ensure compliance with the approved trial protocol and applicable SOPs, 
providing direct access to source data and documents as requested.  
 
15  ETHICAL AND REGULATORY CONSIDERATIONS 
15.1 Research Ethics Committee (REC) review & reports 
The study will be undertaken subject to appropriate Research Ethics Committee (REC) approval and 
local NHS Research & Development approvals. The trial will be conducted in accordance with the 
protocol, the principles of the Declaration of Helsinki and ICH GCP. Any amendments of the protocol 
will be submitted to the Sponsor and REC for approval.  
Substantial amendments that require review by REC will not be implemented until the REC grants a 
favourable opinion and the amendment has been reviewed by relevant NHS R&D departments as 
required. All correspondence with the REC will be retained in the Trial Master File and Investigator 
Site Files. An annual progress report will be submitted to the REC within 30 days of the anniversary 
date on which the original favourable opinion was given, and annually until the trial is declared ended. 
If the study is ended prematurely, the Chief Investigator will notify the REC, including the reasons for 
the premature termination. Within one year after the end of the study, the Chief Investigator will submit 
a final report with the results, including any publications/abstracts, to the REC. 
15.2  Protocol compliance  
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Protocol deviations will be monitored by the CTU and reported to the Chief Investigator and Sponsor 
as appropriate. Significant deviations from the protocol which frequently recur are not acceptable and 
may potentially be classified as a “serious breach”. 
15.3  Notification of serious breaches of GCP and/or the protocol  
A “serious breach” is a breach of the protocol or of the conditions or principles of Good Clinical 
Practice which is likely to effect to a significant degree – 
(a) the safety or physical or mental integrity of the subjects of the trial; or 
(b) the scientific value of the trial 
The Sponsor will be notified immediately of any case where the above definition applies during the trial 
period. The Sponsor is responsible for notifying the REC of a serious breach in any study within seven 
days of the matter coming to their attention.  
15.4  Indemnity and insurance 
The University of Plymouth (as research sponsor) and its research collaborators will be required under 
the terms of their collaboration agreement to maintain public liability, professional indemnity and 
employer's liability insurance (together with such other insurance as the sponsor may require from 
time to time) to cover liabilities arising from the study.  
In addition, each party is required under their collaboration agreement to indemnify the other parties 
and their staff against all claims, proceedings, liabilities, losses and costs incurred by them as a result 
of or in connection with the indemnifying party’s negligent acts or omissions, negligent delivery of its 
work under the study, negligent performance or breach of its obligations under the agreement, wilful 
misconduct or breach of statutory duty (including liability for damage to property, injury or death 
caused by any such negligent act, omission or wilful misconduct). 
 
All participants taking part in the exercise referral scheme will be covered in case of harm by the 
relevant exercise provider’s public liability, professional indemnity and premises insurance.  
16  DISSEMINATION POLICY 
We will use newsletters to maintain contact with participants throughout the trial. At the end of the trial, 
the study team will prepare a plain English summary of the main study results (comparing the two trial 
arms) which will be sent by e-mail or post to study participants. The research team will work with 
stakeholders at each site, and nationally, to help to interpret the results and the implications for policy 
and practice. Dissemination may involve presentation at meetings of relevant support groups or other 
lay audiences, as well as NHS strategy forum at local and national level. 
There will be a standing item on the agenda for each Project Management Group meeting (quarterly) 
on the publication plan and establishing authorship rules. We shall aim to submit the trial Protocol for 
publication no later than the end of the 3 month internal pilot phase of the study. Reports will comply 
with current CONSORT guidelines for publishing randomised trials (http://www.consort-statement.org/) 
and TIDieR guidelines for intervention reporting (http://www.equator-network.org/reporting-
guidelines/tidier/). The study results will be submitted for publication in relevant international, high 
impact, peer reviewed journals. Names of key collaborators and groups who have contributed to the 
trial will be clearly stated in all publications. The study findings will be presented at regional, national 
and international meetings as appropriate.  
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18.  APPENDICES 
18.1  Appendix 1: e-coachER indicative intervention framework  
 
Sequential 
process  
Performance objectives Behaviour Change 
Techniques  
(Michie et al., 2013) 
Implementation Strategy  
Welcome Pack 
and pedometer 
(print) & User 
Guide. 
Introduction to 
web-based 
support for self-
directed PA  
To introduce the user to the 
philosophy of the website to 
become personal coach 
Build on personal support 
provided by ERS using web-
based platform 
Support those who don’t want to 
/can’t engage with ERS 
personnel 
Support achievement of personal 
goals for PA to enhance health  
N/A 
 
Explain philosophy of using website to 
become own personal coach. 
Links provided to local services and 
other self-help resources to highlight 
patient autonomy and choice.  
Offers e-coachER facilitator to help 
with using technology. Provide link to 
IT support in Southampton. 
Step 1 - Thinking 
about the benefits 
of physical activity 
Elevate importance of physical 
activity  
82. Information about 
health consequences 
83. Information about 
emotional 
consequences  
 
 
Quiz to engage participants using 
positive framing.  
Provide evidence of multiple benefits 
of PA especially for relevant health 
condition(s).  
Elicit and address concerns about PA, 
describing support given as part of 
ERS and by website.  
Step 2: Support to 
get active 
To encourage user to access 
and create social support 
networks 
 
To encourage user to take 
advantage of exercise referral 
scheme 
1.Social support 
(practical) 
2.Social support 
(emotional) 
3.Social support 
(unspecified) 
 
 
 
Explain how to make the most out of 
the ERS support to learn how to 
become own personal trainer in future.  
Explain how user can create a 
personal ‘PA challenge’ and share it 
with family, friends, peers, and 
exercise and health professionals. The 
patient may be encouraged to tell 
others about how e-coach has been 
used to support behaviour change.  
Suggest ways of involving family or 
friends in longer-term support for 
continued PA. 
Link to online sources of local support 
(e.g., local walking or jogging group, or 
British Trust for Conservation 
Volunteers). 
How to use website to send 
personalised email/text reminders, 
motivational messages. 
Draw on positive normative beliefs; 
identify benefits of social interaction 
(companionship). Sharing personal PA 
challenge with others, involve friends 
and family, online local support links.   
Identify benefits of informational 
support (from ERS scheme) in addition 
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to emotional support from family and 
friends)  
Step 3: Counting 
your steps 
 
To educate and support the user 
to monitor step counts using a 
pedometer over a week.  
Emphasise personal 
experimentation 
10. Self-monitoring of 
behaviour  
Provide guidance on how to count 
steps/use pedometer.  
Provide guidance on how steps can be 
implemented into lifestyle.  
Encourage self-monitoring using diary.  
Step 4: Making 
your step plans 
To set explicit step count goals 
for the following week 
66. Goal setting 
(behaviour)  
 
 
 
Give rationale and evidence for goal-
setting for graded increase in PA.  
User sets specific, achievable goals 
for next week (e.g. sessions 
completed, step count using the 
supplied pedometers). 
Links provided to local services and 
other resources.  
Step 5: Making 
your activity plans 
To educate and support the user 
to identify behavioural goals 
(types of activities). 
68. Action planning 
 
 
 
User selects walking or ‘other physical 
activities’ (which includes options for 
facility-based activity with practitioner 
support within ERS).  
Present options for facility and 
lifestyle-based activity. 
Sets specific, achievable goals for next 
week with a particular focus on 
avoiding days with less activity by 
planning walking or other activities.   
 
Keeping a PA diary. 
Weekly goal and 
PA review 
To promote adherence and 
graded increase in PA by 
providing tailored feedback and 
advice based on self-reported 
goal progress. 
66. Goal setting 
behaviour 
68. Action planning, 
69. Review behaviour 
goals. 
 
 
User records extent to which goals 
achieved in previous week, gets 
progress graph and personalised 
feedback: 
Praise for any goal achievement, 
encouragement to set more 
challenging goal if not yet meeting 
target PA criteria. 
Encouragement where goals not 
attained, with links to webpages to 
assist with increasing motivation or 
confidence, selecting different 
activities or goals, making better plans, 
accessing support, overcoming 
setbacks  (with links to relevant 
sessions below).  
Each session completed ends with 
new links to reputable information and 
resources (e.g. NHS Choices, 
condition-specific PA advice websites). 
Help user plan gradual increases in 
PA. 
Step 6 – Finding 
ways to achieve 
your plans 
To help the user harness their 
environment to provide support 
for PA  
30. Restructuring the 
physical environment 
Make plan to use environment to 
automatically support PA (with 
examples e.g. fitness equipment in 
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Identifying personal motivations, 
building confidence. 
31. Restructuring the 
social environment  
32. Avoidance / 
reducing exposure to 
cues for behaviour 
living room, route to work/shops that 
involves more PA, committing self to 
specific routine).  
Advise user on how to use website to 
send personalised email/text 
reminders, motivational messages.  
Overcoming barriers in work, leisure, 
home and travel. Building self-efficacy. 
Using smart phone apps for mobile 
support (e.g. PowerTracker, 
MyFitnessPal) 
Invite user to identify personal 
motivations for becoming more active. 
Motivational 
Messages (text 
or/and emails) 
To provide reminders of users 
personal reasons (not 
necessarily health reasons) for 
becoming more active  
15. prompts/cues 
 
Invite user to write motivational 
message to be sent weekly or monthly 
detailing their own motivations for 
becoming more active 
Step 7 – Dealing 
with setbacks 
To provide strategies for 
overcoming relapse in levels of 
PA. 
5. Reduce negative 
emotions 
 
 
 
Identify possible causes of relapse 
(e.g., illness, holidays, change in work 
hours, new caring responsibilities) and 
plan ways to overcome barriers.  
Challenging catastrophic negative 
thoughts about lapses from intended 
PA. 
How to learn from a lapse and plan to 
avoid or overcome in future.  
Provide salient role models of people 
overcoming barriers to successfully 
engage with PA. 
 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Br J Sports Med
 doi: 10.1136/bjsports-2020-103121–8.:10 2020;Br J Sports Med, et al. Taylor A
